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Hormonally-triggered regulatory hierarchies play a major role in organismal 
development. Disruption of a single member of such a hierarchy can lead to irregular 
development and disease. Therefore, knowledge of the members involved and the mechanisms 
controlling signaling through such pathways is of great importance in understanding how 
resulting developmental defects occur. 
Type II transmembrane serine proteases (TTSPs) make up a family of cell surface-
associated proteases that play important roles in the development and homeostasis of a number 
of mammalian tissues. Aberrant expression of TTSPs is linked to several human disorders, 
including deafness, heart and respiratory disease and cancer. However, the mechanism by which 
these proteases function remains unknown. 
The ecdysone-responsive Stubble TTSP of Drosophila serves as a good model in which 
to study the functional mechanism of the TTSP family. The Stubble protease interacts with the 
intracellular Rho1 (RhoA) pathway to control epithelial development in imaginal discs. The 
Rho1 signaling pathway regulates cellular behavior via control of gene expression and actin 
cytoskeletal dynamics. However, the mechanism by which the Stubble protease interacts with the 
Rho1 pathway to control epithelial development, in particular leg imaginal disc morphogenesis, 
has yet to be elucidated. 
The Stubble protein consists of several conserved domains. One approach to a better 
understanding of the mechanism of action of Stubble in regulating Rho1 signaling is to define 
which of the conserved domains within the protease are required for proper function. Sequence 
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analysis of twelve recessive Stubble mutant alleles has revealed that the proteolytic domain is 
essential for proper function. Alleles containing mutations which disrupt regions of the protease 
domain necessary for protease activation or substrate binding, as well as those with deletions or 
truncations that remove some portion of the proteolytic domain, result in defective epithelial 
development in vivo. In contrast, mutations in other regions of the Stubble protein, including the 
disulfide-knotted and cytoplasmic domains, were not observed. 
Another important step for defining the connection between Stubble and Rho1 signaling 
is to identify a Stubble target that acts as an upstream regulator of the Rho1 pathway. We 
performed a genetic screen in which 97 of the 147 Drosophila non-olfactory and non-gustatory 
G-protein-coupled receptors (GPCRs), a family of proteins that has been shown to be protease-
activated and to activate Rho1 signaling, were tested for interactions with a mutant allele of 
Stubble. We found 4 genomic regions uncovering a total of 7 GPCRs that interact genetically 
when in heterozygous combination with a Stubble mutant. Further analysis of these genes is 
necessary to determine if any of these GPCRs is targeted by Stubble during activation of the 
Rho1 pathway. 
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CHAPTER ONE: INTRODUCTION 
Studies of human disease have typically been undertaken in cell culture and mammalian 
model systems. Although these systems are more amenable to genetic manipulation than humans 
themselves, they have significant limitations. Studies in cell culture suffer from the disadvantage 
that cells are usually not observed in a natural context with cell-cell adhesion contacts 
maintained. The extent to which the absence of cell adhesion influences normal cellular behavior 
is unknown. Mammalian model systems permit in vivo manipulation of genes but can be very 
costly to perform.  
Over the past 10 years, Drosophila has emerged as an excellent model in which to study 
human development and disease. Genetic studies can be performed in vivo and at a fraction of 
the cost of mammalian model systems. Major advantages of Drosophila are the sophisticated 
genetic tools that have been developed over the past 100 years, limited genetic redundancy 
allowing gene function to be readily determined, and the discovery of a high degree of 
conservation of gene function with humans. For example, studies in Drosophila of biochemical 
signaling pathways highly conserved between Drosophila and vertebrates has greatly increased 
understanding of the major signaling pathways central to regulation of metazoan development 
and homeostasis (Wassarman et al., 1995; Cadigan and Nusse, 1997; Greenwald, 1998; Johnson 
and Scott, 1998). Drosophila models have also been developed toward identifying the 
mechanisms of a number of human neuropathologies, such as Alzheimer’s, Parkinson’s and 
Huntington’s diseases (Jackson et al, 1998; Warrick et al, 1998; Bilen and Bonini, 2005). In 
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addition, many human genes known to play direct roles in cancers have highly conserved 
orthologs in Drosophila (Hariharan and Bilder, 2006).  
Here I focus on a class of poorly characterized transmembrane serine proteases associated 
with a variety of human pathologies. I hypothesize that studies of these proteases in a Drosophila 
model will be important in establishing a direct link between the action of these proteases and 
human disease. 
Vertebrate type II transmembrane serine proteases and pathology 
Upon sequencing of vertebrate genomes, a surprising number of genes belonging to 
previously identified but sparsely populated protease families have been described. One of these 
families, the mammalian type II transmembrane serine protease (TTSP) family, has rapidly 
grown into a family of 21 membrane–associated proteases with known roles in development and 
homeostasis in a variety of mammalian tissues.  
TTSPs have an atypical mode of insertion into the membrane (intracellular N-terminus 
and extracellular C-terminus; Singer, 1990). All members of this protease family have a similar 
structure, consisting of a short intracellular domain, an extracellular stem region and a highly 
conserved catalytic serine protease domain of the chymotrypsin (S1) fold subfamily (Hooper et 
al., 2001). Within the extracellular stem region, various conserved domains may be found (Szabo 
and Bugge, 2008). TTSPs have been divided into four subfamilies based on a phylogenetic 
analysis of the serine protease domain as well as domain structure of the extracellular stem 
region and chromosomal location of their genes (Figure 1; Szabo et al., 2003). The largest is the 
human airway trypsin (HAT)/differentially expressed in squamous cell carcinoma (DESC) 
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subfamily, followed by the hepsin/TMPRSS/enteropeptidase subfamily, the matriptase 
subfamily, and the corin subfamily. 
The catalytic activity of TTSPs is dependent on the presence of three residues in the 
proteolytic domain, histidine, aspartate, and serine, which make up the catalytic triad. Enzymatic 
activity is further modulated by the structural organization of the substrate binding pocket which 
is responsible for conferring substrate specificity. All TTSPs contain a highly conserved 
activation motif preceding the catalytic domain, suggesting that they are synthesized as single 
chain zymogens and must be activated by proteolytic cleavage after a lysine or arginine residue. 
Upon activation, the catalytic domain remains covalently linked to the membrane-bound stem 
region, and thus to the cell surface, by a conserved disulfide bond (Hooper et al., 2001). The 
specific mechanism of activation of individual TTSPs is unknown. However, all members of the 
TTSP family are trypsin-like, containing Gly216 and Gly226 (chymotrysinogen numbering) at 
the top of the S1 pocket, or primary specificity site, and Asp189 at the bottom of the pocket. 
TTSPs should, therefore, exhibit strong preference for substrates containing an Arg or Lys 
residue in the P1 position (Perona and Craik, 1997), and indeed, all tested members of the TTSP 
family exhibit this Arg/Lys specificity (Takeuchi et al., 2000; Velasco et al., 2002; Hobson et al., 
2004; Szabo et al., 2005). These data suggest that activation may occur upon cleavage by other 





















Figure 1. Predicted domain structures of mammalian type II transmembrane serine proteases. 
Numbers indicate the position of each domain in the amino acid sequence of the zymogen. 
Figure and legend taken in modified form from Szabo and Bugge, 2008. 
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The TTSP family is of particular clinical interest because misexpression of several of its 
members has been linked to a number of pathologies. At least 15 different mutations in the 
TMPRSS3 gene are associated with non-syndromic congenital and childhood onset autosomal 
recessive deafness in human patients (Ben-Yosef et al., 2001; Masmoudi et al., 2001; Scott et al., 
2001; Wattenhofer et al., 2001; Ahmed et al., 2004; Wattenhofer et al., 2005; Elbracht et al., 
2007; Guipponi et al., 2008). Interestingly, mice deficient for another TTSP, hepsin, also display 
hearing loss and developmental defects in the inner ear (Guipponi et al., 2007), suggesting that 
several TTSPs may play a cooperative role in normal inner ear development. 
Several TTSP family members have been implicated in cancer. Hepsin is consistently 
misexpressed and the most upregulated gene in prostate cancer, expressed solely on the surface 
of prostate tumor cells (Dhanasekaran et al., 2001; Luo et al., 2001; Magee et al., 2001; Stamey 
et al., 2001; Welsh et al., 2001). Upregulation of hepsin in vivo causes disruption and 
disorganization of the prostate basement membrane and leads to metastasis and cancer 
progression in mice (Klezovitch et al., 2004). Misexpression of another TTSP, TMPRSS2, is also 
associated with prostate cancer progression. One study identified two genetic abnormalities in a 
subset of prostate cancer patients. Approximately 38% of patients showed a duplication of the 
TMPRSS2 gene, while a single individual with aggressive prostate cancer showed a 7-bp deletion 
which resulted in a frameshift mutation and truncation of the protein after incorporation of only 
one catalytic triad residue (Vaarala et al., 2001). Other studies have shown that a majority of 
prostate cancer patients exhibit chromosomal rearrangements leading to fusion of the TMPRSS2 
gene with the ERG, ETV1, and ETV4 genes which encode oncogenic transcription factors of the 
ETS family (Soller et al., 2006; Tomlins et al., 2005, 2006). TMPRSS2 is an androgen-responsive 
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gene (Lin et al., 1999; Jacquinet et al., 2001), thus fusions with TMPRSS2 result in androgen-
dependent regulation of ETS transcription factors and subsequent overexpression in androgen-
sensitive prostate tissue.  
Misexpression of matriptase, was first noted in breast carcinoma (Shi et al., 1993; Lin et 
al, 1997) and has since been described in benign and malignant epithelial tumors of diverse 
origins (reviewed in Bugge et al., 2007). Matriptase is expressed in a variety of embryonic and 
adult tissues, but its expression is limited to the epithelial compartments of these tissues 
(Takeuchi et al., 1999; Oberst et al., 2003; List et al., 2006; Netzel-Arnett et al., 2006; Fan et al., 
2007; Szabo et al., 2007). Tight regulation of matriptase activity in these tissues is essential for 
normal epithelial development. As shown by List et al. (2005), even a modest overexpression in 
the epidermis of transgenic mice leads to induction of spontaneous squamous cell carcinomas. In 
addition to an association with epithelial cancers, misexpression of matriptase is linked to 
additional pathologies involving the skin and hair, further strengthening the necessity for proper 
regulation of matriptase activity during development. Matriptase-deficient mice develop to term 
but die shortly after birth due to severe dehydration resulting from greatly impaired epidermal 
barrier function. These mice also display absence of whiskers, hair follicle hypoplasia, and 
accelerated apoptosis of immature T cells in the thymus (List et al., 2002). Recently, Basel-
Vanagaite et al. (2007) reported a single amino acid substitution (G827R) in a highly conserved 
glycine hinge residue in the protease domain of human ST-14, which encodes matriptase. This 
mutation is found in patients with ichthyosis with hyptrichosis (ARIH) syndrome, a rare 
autosomal recessive form of skin disease. Patients present with mild to moderate ichthyosis, 
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indicative of impaired barrier function, and follicular hypoplasia characterized by sparse, fragile, 
brittle, dry and lusterless hair that shows slow growth. 
Finally, the corin subfamily of TTSPs has been linked to heart development and 
cardiovascular disease. A minor allele of corin, a TTSP confined to the cardiac myocytes of the 
atrium and ventricle (Yan et al., 1999; Hooper et al., 2000), was recently associated with a 
human population with high systolic blood pressure and an increased risk for chronic 
hypertension (Dries et al., 2005).  
Because misexpression of TTSPs is associated with a variety of human pathologies, 
understanding the mechanism of action of this class of proteins is crucial for disease treatment 
and prevention. One approach to understanding the mechanism of action of TTSPs is to 
determine the relationship between the conserved domains contained within the proteases and in 
vivo function of the protease. It has been established that a protease domain with an intact 
catalytic triad is necessary for activation and subsequent catalytic activity (Oberst et al. 2003; 
Hammonds and Fristrom, 2006). The functions of the various conserved domains found in 
TTSPs are generally not well understood; however, for several proteases, a requirement for these 
domains has been demonstrated. For example, matriptase is a multi-domain TTSP containing a 
SEA (sperm protein, enterokinase, and agrin) domain, two tandem CUB (C1r/s, Uegf, and bone 
morphogenic protein-1) domains, and four tandem LDLRA (low density lipoprotein receptor 
class A) domains within the extracellular region (see Figure 1). A series of mutations made in 
each of these domains indicates that intact function of each domain type is essential for 
matriptase activation (Oberst et al., 2003). Upon mutation of a putative glycosylation site in the 
first CUB domain, a dramatic reduction of protease-inhibitor complex formation and 
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immunoreactivity with M69 mAb, an antibody which recognizes only the two-chain activated 
matriptase, was observed. This indicates that glycosylation of the first CUB domain is necessary 
for protease activation. The LDLRA domain contains a “calcium cage,” an octahedral 
arrangement of a Ca2+ atom, which is involved in the binding of this domain to substrates. Point 
mutation of critical residues of the calcium cage previously shown to be necessary for substrate 
binding (Esser et al., 1988) was made in each of the four LDLRA domains of matriptase. For 
each domain separately and all four domains simultaneously, this mutation inhibited protease-
inhibitor complex formation and M69 immunoreactivity, suggesting that all of the LDLRA 
domains are essential for activation. Interestingly, efficient matriptase activation was observed 
following deletion of all four LDLRA domains. This suggests that the LDLRA domains may 
serve dual functions as binding domains for activators of matriptase and as autoinhibitory 
domains when no activators are present. Finally, the SEA domain contains a consensus cleavage 
site which serves as a target for proteolytic processing. Cleavage at this site converts matriptase 
into a smaller form lacking the N-terminal and transmembrane regions. When N-terminal 
proteolytic processing is inhibited via mutation of the cleavage site, no protease activation occurs 
in in vitro assays, indicating that N-terminal cleavage is necessary for enzyme activation (Oberst 
et al., 2003).  
TMPRSS3, another multi-domain protease, consists of a single LDLRA domain followed 
by a single SRCR (scavenger receptor cysteine rich) domain in its extracellular stem region (see 
Figure 1). Two missense mutations have been identified in the LDLRA domain. One of these 
mutations affects a highly conserved residue and is believed to impair the calcium binding site of 
the domain (Wattenhofer et al., 2002). The second mutation affects the last residue of the 
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LDLRA domain, which is potentially involved in binding with extracellular molecules (Ben-
Yosef et al., 2001). These mutations result in almost complete loss of protease activity in vitro 
and are associated with hearing loss (Guipponi et al., 2002). In addition, two missense mutations 
in highly conserved residues of the TMPRSS3 SRCR domain have been identified in patients 
with congenital and childhood onset hearing loss (Wattenhofer et al., 2002; Hutchin et al., 2005). 
One of these SRCR mutations also results in almost complete loss of protease activity in in vitro 
assays (Guipponi et al., 2002). 
It is important to note that in most cases the linkage between mutant TTSP alleles and 
human disease has not been directly established. Thus, an assay system that could determine the 
activity of mutant TTSPs in vivo, and provide functional genetic rescue capability would be of 
great benefit to this field. In the section on future studies (see discussion) I describe how the 
Drosophila model system used in these studies could be utilized to this end.  
The Drosophila Stubble TTSP as a model to study the mechanism of action of the TTSP family 
The only non-vertebrate TTSPs that have been characterized are the Drosophila Stubble 
and corin proteases and their orthologues in other arthropod species (Beaton et al., 1988; Appel 
et al., 1993; Irving et al., 2001; Zou et al., 2006). The Stubble locus encodes a typical member of 
TTSP family and is required for normal leg, wing and bristle morphogenesis. Based on sequence 
analysis of the protease domain, the Stubble protease shows greatest sequence similarity to the 
matriptase subfamily in vertebrates. The Stubble protease ends in a trypsin-like serine protease 
domain of 244 amino acids and contains a 35-residue disulfide knotted domain, or clip domain, 
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specific to arthropods, within its extracellular stem (Figure 2; Appel et al., 1993). The 
cytoplasmic domain is 58 amino acids in length and contains one putative protein kinase C 
(PKC) phosphorylation site, one putative cAMP phosphorylation site, and 3 putative N-
myristoylation sites. The PKC phosphorylation consensus pattern, SRR, where serine is the 
phosphorylation site, is found between residues 49 and 51 in the Stubble protein. The cAMP 
phosphorylation site has the consensus pattern RRsT and is found between residues 14 and 17. 
The consensus patterns for N-myristoylation present in Stubble are GSrgSG at residues 38-43, 
GSggAA at residues 41-46 and GGaaAR at residues 43-48. The N-terminus of the Stubble 
protein is hydrophilic, preceding a hydrophobic transmembrane anchor sequence. The 
transmembrane domain is flanked by charged regions (positive intracellular and negative 
extracellular) that are required for correct orientation of the protein in the membrane (see figure 















Figure 2. Structure of the active Stubble protease. 
The Stubble protease is composed of four major regions: the intracellular (cytoplasmic) domain, 
the transmembrane domain, the stem region, and the proteolytic domain. A disulfide knotted 
domain, specific to arthropods, is found within the stem region. 
 
The disulfide knotted domain, the only conserved domain contained within the 
extracellular stem of the Stubble protease, is connected to the protease domain by a linking 
sequence of 329 amino acids, substantially longer than the 23 to 101 amino acid residues found 
in most other clip domain-containing proteins (Jiang and Kanost, 1999). Disulfide knotted 
domains are held together by a series of three disulfide bonds which result in a compactly folded 













designation of clip domain (Iwanaga et al., 1998). In addition to disulfide bridges formed within 
the clip and proteolytic domains an additional disulfide bond links the proteolytic and stem 
regions in the activated protease ensuring that the protease remains tethered to the membrane 
upon activation cleavage (Figure 3; Muta et al., 1990, 1993). Several functions have been 
proposed for disulfide knotted domains. They may function as mediators of interactions between 
proteases and their activators or substrates. It is also possible that disulfide knotted domains act 
as inhibitors of the protease domains to which they are linked. It is known that certain proteases, 
such as the cysteine protease cathepsin L and convertases of the serine protease subtilisin family, 
can be inhibited by their own propeptides (Carmona et al., 1996; Boudreault et al., 1998). 
Supporting this idea is the fact that disulfide knotted domains are small structures stabilized by 
disulfide bonds, common features of many canonical serine-type protease inhibitors (Bode and 
Huber, 1992). However, mutational analysis of the cysteine residues in the disulfide knotted 
domain of snake, a serine protease involved in dorsoventral patterning in Drosophila, argues 
against an autoinhibitory role (Smith et al., 1993). Alteration of five of the six individual cysteine 
residues to serine resulted in a failure of the protease to phenotypically rescue snake-deficient 
embryos. The remaining cysteine residue exhibited some phenotypic rescue upon alteration to 
serine, but activity was greatly reduced from wild type. Simultaneous alteration of cysteine pairs 
involved in disulfide bridge formation as well as deletion of the entire disulfide knotted domain 
also resulted in a failure to rescue snake-deficient animals. These data suggest that conserved 
disruption or removal of the disulfide knotted domain leads to a loss of snake activity. The 
opposite effect, constitutive activation, would be expected if the disulfide knotted domain acted 











Figure 3. Structural organization of disulfide knotted (clip) domain proteases.  
Clip domain proteases contain a linker region of variable length connecting the clip domain to a 
carboxy-terminal serine protease domain. A disulfide bond between conserved cysteine residues 
in the stem and proteolytic domains ensures that these domains remain covalently attached 
following activation of the zymogen. Figure and legend taken from Jiang and Kanost, 2000. 
 
In this study I have chosen to use the Drosophila Stubble protease as a model to study 
TTSP action in epithelia. The Stubble locus is transcriptionally induced in response to the steroid 
hormone 20-hydroxyecdysone, a major mediator of morphogenetic events (Appel et al., 1993). 
Upon induction by ecdysone, the Stubble protein is localized to the apical cell membrane of 
developing leg and wing imaginal discs where it functions to control epithelial morphogenesis 
(von Kalm et al., 1995; Hammonds and Fristrom 2006). Studies in our laboratory have shown 
that in leg imaginal discs Stubble acts upstream of the monomeric GTPase Rho1, a major 
regulator of the actin cytoskeleton, and that this interaction occurs via an outside-in signaling 
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mechanism (Bayer et al., 2003). Thus, further studies of the mechanism underlying the 
interaction between Stubble and Rho1 are likely to improve our understanding of vertebrate 
TTSP action in development, homoestasis and disease.  
In the following sections, I will describe in more detail the process of leg imaginal disc 
morphogenesis, the involvement of the Stubble protease in this process and the interaction 
between Stubble and Rho1 signaling in control of epithelial morphogenesis. 
Leg imaginal disc development 
In Drosophila, the steroid hormone 20-hydroxyecdysone (ecdysone) is necessary to 
mediate a major portion of the developmental process, metamorphosis. During metamorphosis, 
adult structures such as legs, eyes and wings arise from small epithelial organs called imaginal 
discs. Imaginal discs arise from invaginations of the embryonic epidermis (Cohen, 1993). During 
larval development, imaginal discs grow by mitotic division. Proliferation of the discs proceeds 
until just prior to metamorphosis, at which point the leg disc, for example, is simply a sac-like 
epithelial structure connected to the interior surface of the epidermis by a stalk where the original 
invagination occurred. This sac is composed of a thick folded columnar epithelium on one side, 
resembling a Danish pastry, and a flat squamous epithelium on the other. (Fristrom and Fristrom, 
1993). At the end of larval development, a sharp increase in the titer of ecdysone occurs. This 
increase inhibits cell proliferation and triggers morphogenesis of the imaginal discs (Figure 4). It 
is during the subsequent 12-hour prepupal period of development that the leg and wing discs, for 
example, give rise to structures which resemble the adult appendages, and then evert to the 
outside of the body wall. The prepupal development of leg imaginal discs is depicted in Figure 5. 
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Following stimulation by the metamorphic pulse of hormone, leg discs elongate and evert to the 
outside of the animal. Elongation of the presumptive leg is driven by changes in apical cell shape 
leading to unfolding of the disc and shaping of the epithelium into a tube-like structure. 
Contraction of the actin-myosin contractile belt is the primary force underlying apical cell shape 
changes in elongating leg discs (von Kalm et al., 1995). When actin-myosin contraction is mis-
regulated, apical cell shape changes are abnormal resulting in a malformed leg and wing 
phenotype, exemplified by legs that are shortened, thickened and twisted compared to normal 













Figure 4. Fluctuations in ecdysone titer trigger imaginal disc morphogenesis at the onset of 
metamorphosis. 
Proliferation of the leg imaginal discs occurs throughout larval development. The sharp rise in 
ecdysone titer (red line) occurring at 120 hours post egg laying inhibits further proliferation and 
triggers the elongation of the disc and subsequent eversion. Time 120h represents the end of 
larval development and the beginning of the 12 hour prepupal period and metamorphosis. At this 
point, the time line resets to 0h. A major phase of prepupal leg morphogenesis occurs during the 
first 6 hours of the prepupal period. Further morphogenesis and differentiation occur during the 
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Figure 5. Cell shape changes in leg imaginal discs during elongation. 
(a-d) Confocal micrographs of prepupal discs stained with phalloidin to visualize filamentous 
actin. (a) A leg at the beginning of the prepupal period. (b) A leg after 6 hours of prepupal 
development. (c and d) Apical view in cross-section indicated by arrows in a and b. Note the 
change in apical cell shape from anisometric to isometric in the elongating disc. (e) A schematic 
of cell shape changes that occur during elongation of the leg disc. (f) Apical view of a leg disc 
stained for Drosophila non-muscle myosin indicating the location of the actin-myosin contractile 














Figure 6. The malformed phenotype. 
Defects in genes controlling cell shape changes result in malformed legs and wings (right panels) 
compared to wild-type (left panels) (from Bayer et al., 2003). Note that the mutant legs are 
shortened, thickened and twisted compared to normal legs. Wings are crumpled and frequently 
display blisters (separation of the wing epithelial bilayer). 
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Stubble function in normal development 
The Stubble protein is expressed at the apical surface of leg imaginal disc cells, and 
multiple mutations in the Stubble locus have been identified which lead to the malformed leg 
phenotype. The malformed phenotype observed in Stubble mutant animals is caused by a failure 
of cell shape change in leg disc epithelia (Condic et al., 1991). The Stubble protease has also 
been linked to the Rho1 signaling pathway and control of actin cytoskeletal dynamics (Bayer et 
al., 2003; see below). Thus, a major role for the Stubble protease in leg disc development may be 
control of cell shape changes through regulation of the actin cytoskeleton. 
Mutations in Stubble interact genetically with mutations in several members of the Rho1 
signaling pathway in leg imaginal discs. Rho1 pathway members showing moderate to strong 
interaction with Stubble include DRhoGEF2, Rho1, Rho kinase (drok), zipper (non-muscle 
myosin II heavy chain), cofilin phosphatase, and myosin phosphatase (shown in red in Figure 7). 
In addition to genetic interaction data, leg malformation associated with overexpression of 
Stubble during leg morphogenesis can be suppressed by reducing Rho1 gene dosage (Bayer et 
al., 2003). These data suggest that Stubble acts upstream of the Rho1 pathway and may be 
required for temporal and spatial activation of Rho1 signaling during leg disc elongation.  
The Rho family of small guanosine triphosphates (GTPases) plays an important role in 
the regulation of epithelial morphogenesis. Rho1, Rac, and Cdc42 are three well-studied 
members of this family that act to regulate a variety of epithelial processes including but not 
limited to cell growth, cell division, cell adhesion and apical-basal and planar cell polarity. 
Regulation occurs by control of actin cytoskeletal dynamics and nuclear gene transcription 
through nucleation, polymerization, and depolymerization of actin filaments, and by control of 
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the actin-myosin contractile apparatus. Rho1, Rac, and Cdc42 regulate actin dynamics in part 
through involvement in intracellular signaling complexes in vertebrate and invertebrate epithelia 

















Figure 7. Rho1 regulation of actin contraction and filamentation. See text for details.  
Drosophila orthologs of the vertebrate Rho kinase (drok), myosin regulatory light chain (sqh; 
Spaghetti Squash), non-muscle myosin II heavy chain (zipper), myosin phosphatase (mbs; 
myosin binding subunit), and cofilin phosphatase (ssh; slingshot) are indicated. Mutations in 
Rho1 pathway genes that interact genetically with Stubble mutations in leg imaginal discs are 
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Studies in vertebrate systems have provided a model for Rho1 signaling which leads to 
contraction of the actin-myosin contractile belt in epithelia (Figure 7). While only one Rho 
protein, Rho1, is present in Drosophila, three equivalent proteins, RhoA, RhoB and RhoC are 
present in vertebrates. Functionally, Rho1 is believed to be most similar to the vertebrate RhoA, 
though at the amino acid level, percent identity between Rho1 and human RhoA, B and C is 
identical (Hariharan et al., 1995). Rho1-specific guanine nucleotide exchange factors (RhoGEFs) 
are activated by extracellular signals that trigger a relocation of the GEF to the plasma membrane 
where it forms a complex with its target Rho1 GTPase (Zheng et al., 1996). Activated RhoGEF 
promotes cycling of the inactive form of Rho1 (GDP-bound) to the active form (GTP-bound). 
ERM (ezrin, radixin, and moesin) family proteins on the plasma membrane inhibit the 
association of guanine dissociation inhibitors (GDIs) with the inactive Rho1, thus reinforcing 
Rho1 activation through a positive feedback loop (Tsukita et al., 1997; Matsui et al., 1998). ERM 
proteins may also be involved in a negative feedback loop regulating Rho1 activity, thus fine 
tuning the rate of cycling of Rho1 between the GDP- and GTP-bound states (Speck et al., 2003). 
Activated Rho1 then stimulates the downstream effectors Rho kinase and Diaphanous. Activated 
Rho kinase stimulates at least two different substrates, splitting the pathway into a myosin-
dependent branch and a Lim kinase-dependent branch. In the myosin-dependent branch, Rho 
kinase phosphorylates and thus activates myosin regulatory light chain (Sqh) (Amano et al., 
1996) and inhibits myosin light chain phosphatase (Kimura et al., 1996). Activation of the 
myosin regulatory light chain leads to activation of myosin II heavy chain (Zipper) and 
contraction of the actin-myosin belt. In the Lim kinase-dependent branch of the pathway, Rho 
kinase activates Lim kinase, which inhibits the turnover of F-actin by cofilin, leading to 
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stabilization and accumulation of F-actin and subsequent cell shape change (Maekawa et al., 
1999). Activated Diaphanous must cooperate functionally with Lim kinase to induce 
accumulation of F-actin (Geneste, Copeland and Treisman, 2002). While Rho kinase-Lim kinase 
signaling inhibits F-actin turnover, Rho1 promotes F-actin assembly by binding to and thus 
relieving autoinhibition of Diaphanous, which, in conjunction with profilin, nucleates actin 
filaments resulting in formation of unbranched F-actin filaments (Watanabe et al., 1999; Pruyne 
et al., 2002; Sagot et al., 2002). 
Rho signaling and disease 
Studies have recently shown Rho family proteins to be involved in tumorigenesis. The 
mechanisms by which these proteins are involved in cancer progression have not been defined 
but the links existing between Rho proteins and cancer are considerable. Misexpression of 
members of the RhoA signaling pathway in vertebrates has been associated with a variety of 
cancers of epithelial origin (reviewed in Benitah et al., 2004). Given that TTSPs are thought to 
be involved in disease progression via interaction with intracellular signaling pathways and that 
the RhoA pathway in vertebrates has been linked to disease, the interaction of the Stubble 
protease with the Rho1 signaling pathway in Drosophila serves as an excellent model in which 
to study the mechanistic role of TTSPs in disease. 
G protein-coupled receptors are a potential link between Stubble proteolytic activity and Rho1 
signaling 
The genetic data presented above strongly implicate Stubble in Rho1 signaling. 
Interactions have been detected between mutations in the Stubble gene and DRhoGEF2, Rho1, 
 21
drok, cofilin phosphatase, myosin phosphatase, zipper and DSRF (shown in red in Figure 7). 
Also, a reduction in the gene dosage of Rho1 suppresses the severe malformed leg phenotype 
induced by overexpression of Stubble (Bayer et al., 2003). As a result of these studies, it has 
been proposed that the Stubble protease operates through an “outside-in” signaling mechanism 
during leg development to either act in parallel with or directly regulate Rho1 signaling, though 
the mechanism by which this occurs is unknown. 
In an attempt to better understand the mechanism by which Stubble acts, a genome-wide 
screen for genes that interact with Stubble to control leg development was initiated (von Kalm et 
al., unpublished). Using a deletion strategy, 80Mb (85%) of the Drosophila autosomal genome 
was screened for chromosomal intervals containing genes whose products interact with Stubble 
during epithelial morphogenesis to regulate cell morphology. Twelve intervals containing 
interacting gene products were identified. Six of these intervals uncover heterotrimeric guanine 
nucleotide-binding protein (G protein)-coupled receptors (GPCRs), a family of proteins through 
which Stubble could potentially link to intracellular Rho1-mediated signaling events. 
In addition to Stubble, four vertebrate type II transmembrane serine proteases also appear 
to operate through an “outside-in” signaling mechanism. Enteropeptidase, HAT (human airway 
trypsin), Matriptase/MT-SP1, and TMPRSS2 have all been linked to intracellular signaling 
events which involve PAR (protease-activated receptor)-2 (Takeuchi et al., 2000; Cottrell et al., 
2004; Chokki et al., 2005; Wilson et al., 2005). PARs are a subset of G protein-coupled receptors 
that are activated by proteolytic cleavage of the receptor, creating a tethered ligand that cannot 
diffuse away, rather than by simple ligand occupancy (Vu et al., 1991). Proteolytic activation of 
PARs is mediated by the serine protease family. PARs are expressed in a number of normal cell 
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types as well as in tumor cells and invasive cell lines and are found in carcinoma specimens. 
PAR-2, specifically, is expressed in a number of cell types including vascular endothelial cells, 
myocytes, fibroblasts, immune cells, neurons, glial cells and a variety of epithelial cells. The 
physiological role of the PARs in different cell types includes, but is not limited to, control of 
homeostasis, inflammation, pain and healing, and proliferation (MacFarlane et al., 2001). 
G protein-coupled receptors, which are able to activate heterotrimeric G proteins, are 
known to be major upstream regulators of Rho signaling. G proteins couple activated GPCRs to 
the initiation of intracellular signaling responses by acting on downstream effector molecules. 
Several Rho-specific GEFs have been shown to act as effectors of various G protein α subunits 
in mammalian systems, thus coupling activation of Rho signaling with G protein signaling 
events. A number of distinct G protein α subunits have been identified and are divided into four 
families based on amino acid sequence similarity and function: Gs, Gi, Gq and G12 (Wilkie et al., 
1992). PDZ-RhoGEF, p115 RhoGEF and leukemia-associated Rho guanine nucleotide exchange 
factor (LARG) interact with the G12 family subunits Gα12 and Gα13 through their regulator of G 
protein signaling (RGS) domains (Hart et al., 1998; Kozasa et al., 1998; Fukuhara et al., 1999, 
2000). LARG has also been shown to cooperate with activated Gαq/11, as well as Gα12/13, to 
stimulate activation of RhoA, suggesting that LARG can also serve as an effector for Gq coupled 
receptors (Booden et al, 2002; Vogt et al., 2003). More recently, p63RhoGEF was shown to 
couple Gq/11- but not G12/13-coupled receptors to Rho signaling (Lutz et al., 2005, 2007). It was 
further demonstrated that the p63RhoGEF-induced enhancement of RhoA activation occurred by 
direct protein-protein interaction between the C-terminus of p63RhoGEF and active Gαq or Gα11. 
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Aims of this study 
Localization to the cell surface puts type II transmembrane serine proteases in an 
excellent position to mediate signal transduction between intracellular signaling pathways and 
the extracellular environment and to regulate cellular responses. Indeed, a number of TTSPs 
have been shown to play important roles in the normal development of tissues and have been 
associated with a variety of human diseases, including heart disease and cancer. To understand 
the distinct roles that TTSPs play in tissue development and disease, it is necessary to define 
their function on a mechanistic level. Two approaches to a better understanding of the 
mechanism of action of TTSPs in regulating cellular response are to define which of the 
conserved domains within the proteases are required for proper function and to identify TTSP 
targets that could act as upstream regulators of intracellular signaling and response pathways. 
Because the Stubble TTSP is known to play a role in epithelial morphogenesis through 
interaction with the intracellular Rho1 signaling pathway, it serves as an excellent model in 
which to study the mechanism of action of the TTSP family.  
In an attempt to identify the essential conserved domains of the Stubble protein, I 
sequenced twelve recessive mutant alleles of Stubble. Coding region mutations were identified in 
nine of these alleles and all but one localize to the protease domain. The remaining mutation 
localizes to the stem region and affects the amino acid residue directly preceding the disulfide 
knotted domain. Mutations in other regions of the Stubble protein, including the disulfide-
knotted and cytoplasmic domains, were not observed. These data identify the protease domain as 
essential for function but do not rule out the remaining domains as necessary functional 
components. 
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Because G protein-coupled receptors have been identified as TTSP targets and have also 
been linked to the Rho1 pathway via activation of G protein α-subunits, I asked if GPCRs might 
be targeted by Stubble to regulate Rho1 signaling. These experiments involved a genetic screen 
of the non-gustatory and non-odorant GPCRs in the Drosophila genome for interactions with a 
mutant Stubble allele. At present, 97 of the 147 total non-gustatory, non-odorant receptors have 
been tested, and 4 genomic regions which interact genetically with the Stubble mutant have been 
identified. These regions uncover a combined total of 8 GPCRs. Further analysis is necessary to 
determine if any of these GPCRs are targeted by Stubble leading to activation of the Rho1 
pathway. 
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CHAPTER TWO: METHODS 
Drosophila stocks 
Drosophila sbd, Rho1, and zipper mutant alleles used in this study are described in Table 
1. All sbdE(br) stocks were obtained from R. Ward (University of Kansas; Ward et al. 2003). All 
deficiency stocks used in this study were obtained from the Bloomington Drosophila Stock 
Center at Indiana University (Bloomington, IN). Transgenic stocks are described below. All 
stocks were maintained at 25º on standard cornmeal/yeast/agar medium. 
Genetic complementation analysis 
To genetically test the activity of the sbd mutants, second-site noncomplementation 
(SSNC) assays were performed by mating animals heterozygous for sbd mutations with animals 
heterozygous for other mutant genes of interest. Leg malformation was scored in the doubly 
heterozygous F1 progeny class (i.e., */+; sbd/+). Genotypes generated to test for dominant 
interactions (i.e., Rho172O/+; sbd*/sbd1) were obtained by mating animals carrying sbd 
mutations, e.g., sbd*/TM6B, Tb Hu e, to Rho172O/CyO-CR2, P{sevRas1.V12}FK1; sbd1/TM6B, 
Tb Hu e animals. In each cross, 7-10 virgin females were mated with 5 males. All crosses were 
set up in duplicate. Cultures were incubated at 25º for either 3 or 5 days followed by transfer of 
adults to fresh medium. Subsequent cultures were incubated for 2 or 5 days, respectively, until a 
total of 6 cultures per cross were generated. 
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Table 1. Mutant alleles of stocks used in this study 
Mutant Allele Mutagen Reference 
sbdE(br)20 EMS Ward et al. (2003) 
sbdE(br)48 EMS Ward et al. (2003) 
sbdE(br)228 EMS Ward et al. (2003) 
sbdE(br)448 EMS Ward et al. (2003) 
sbdE(br)536 EMS Ward et al. (2003) 
sbdE(br)623 EMS Ward et al. (2003) 
sbdPNR11 EMS Heitzler and Simpson (1991) 
sbdVE3 EMS Heitzler and Simpson (1991) 
sbd1 Spontaneous Dobzhansky (1930) 
sbd206 EMS Hecht (1989) 
sbd46 EMS R. Ruggiero (unpublished data) 
sbd173 EMS R. Ruggiero (unpublished data) 
sbd241 EMS R. Ruggiero (unpublished data) 
sbd258 EMS R. Ruggiero (unpublished data) 
sbd266 EMS R. Ruggiero (unpublished data) 
sbd277 EMS R. Ruggiero (unpublished data) 
Df(3R)sbd105 X ray Beaton et al. (1988) 
Rho1J3.8 EMS Halsell et al. (2000) 
Rho1E3.10 EMS Halsell et al. (2000) 
Rho172O P-element 
insertion/excision 
Strutt et al. (1997) 
Rho1k02107b P-element insertion Magie et al. (1999) 
zipEbr EMS Gotwals and Fristrom (1991); Gotwals (1992); 
Halsell et al. (2000) 
 
 
To screen for G-protein-coupled receptors (GPCRs) potentially involved in leg 
morphogenesis, SSNC assays were performed by mating heterozygous Stubble mutant animals 
(i.e., red Sb63be/TM6B, Tb Hu e) with heterozygous or homozygous animals carrying a 
deficiency uncovering the GPCR, or a transposable element insertion or mutation in the GPCR. 
Leg malformation was scored in the doubly heterozygous F1 progeny class (i.e., */+; Sb/+). 
Secondary SSNC assays of mutants found to interact in the primary screen were conducted by 
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mating animals carrying interacting mutations with animals heterozygous for other mutant alleles 
of interest (i.e., Sb70, Rho1E3.10, Rho1J3.8, Np125A and Np2) and by mating heterozygous Stubble 
mutant animals (i.e., red Sb63be/TM6B, Tb Hu e) with animals carrying deficiencies overlapping 
the region uncovered by the original interacting deficiency. All crosses were set up in duplicate. 
Cultures were incubated at 25º for 5 days followed by transfer of adults to fresh medium. 
Subsequent cultures were incubated for 5 days, until a total of 6 cultures per cross were 
generated. 
Lethal-phase analysis of sbd mutant alleles 
Embryonic lethality was assessed by collecting 0- to 2-hr embryos from sbd/TM6B, 
P{w+, UbiGFP} stocks. Embryos were aged to 15 hours at 25ºC and dechorionated in 50% 
bleach for 3 minutes. Homozygous sbd embryos were then selected based on absence of green 
fluorescent protein (GFP) expression. Homozygous embryos were aged at 25ºC to 48 hours post-
egg laying, and dead embryos were counted. Embryonic lethality was calculated as (number of 
dead embryos/total number of mutant embryos) x 100. Dependent on the number present, 34-100 
sbd mutant embryos were assessed in each experiment, and each experiment was done in 
triplicate. Larval lethality was determined by collecting homozygous mutant sbd first instar 
larvae derived from sbd/TM6B, P{w+, UbiGFP} stocks on the basis of absence of GFP 
expression. Mutant larvae were allowed to develop for 7-10 days at 25ºC, and pupae were 
counted. Larval lethality was calculated as [(total number of mutant larvae – number of 
pupae)/total number of mutant larvae] x 100. Dependent on the number of hatchers, up to 100 
larvae were assessed in each experiment, and each experiment was done in triplicate. Pupal 
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lethality was determined by allowing pupae from the larval lethality assay to eclose. Adults were 
counted and pupal lethality was calculated as [(total number of pupae – number of adults)/total 
number of pupae] x 100. 
Genetic characterization of sbd alleles 
To genetically characterize the sbd alleles, 150 virgin sbd105 e ca/TM6B, P{w+, UbiGFP} 
females and 150 sbd*/TM6B, P{w+, UbiGFP} females were mated separately to 75 sbd*/TM6B, 
P{w+, UbiGFP} males. 0-2 hour embryos were collected on grape plates and aged to 15-17 hours 
at 25º, at which time they were dechorionated in 50% bleach for 3 minutes. Homozygous sbd* 
and trans-heterozygous sbd105 e ca/sbd* mutant embryos were then selected based on absence of 
green fluorescent protein (GFP) expression and placed on a fresh grape plate. Embryos were then 
aged at 25º to 48 hours post-egg-laying, at which time dead embryos were counted and hatched 
larvae were transferred to a fresh plate with a strip of thin yeast paste and stored at 25º in a 
humid chamber. Every 24 hours, dead larvae were counted, larval progress was observed and 
noted, and larvae were transferred to a fresh plate containing a strip of thin yeast paste. Upon 
reaching the third instar stage, larvae were placed in a vial containing Drosophila medium and 
aged at 25º for a period of time sufficient for pupariation and eclosion of any viable adults. 
Development and lethal-phase of homozygous sbd* mutants was compared to that of sbd105 e 
ca/sbd* mutant trans-heterozygotes. Any sbd* allele exhibiting an identical developmental 
pattern and lethal-phase as trans-heterozygotes is considered to be a null allele. 
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Sequence analysis of sbd mutant alleles 
To identify mutations in sbd alleles, genomic DNA from mutant animals in homozygous 
and various heterozygous conditions (Table 2) was isolated via phenol-chloroform extraction 
followed by ethanol precipitation. Twenty adults were collected for each mutant genotype 
analyzed and ground using a motorized pestle in a 1.5 mL microcentrifuge tube containing 200μl 
homogenizing buffer (100mM NaCl, 200mM sucrose, 100mM Tris-Cl, pH 9.1, 50mM EDTA, 
0.5% SDS). Upon homogenization, an additional 500μl homogenizing buffer was added and 
used to rinse the pestle. Phenol-chloroform extraction was performed by adding 250μl phenol 
and 250μl chloroform (chloroform:isoamyl alcohol 24:1) and vortexing for 30 seconds, followed 
by centrifugation at 4º for 5 minutes at 14,000 rpm. After spinning, the aqueous phase was 
removed and a second phenol-chloroform extraction was performed as above. 500μl of the final 
aqueous phase was placed in a clean microcentrifuge tube and prepared by ethanol precipitation 
with 50μl 3M NaAc (pH 4.8-5.2) and 1mL cold 100% ethanol. Samples were mixed and spun at 
4º for 5 minutes at 14,000 rpm. After centrifugation, the supernatant was decanted and pellets 
were dried in a vacuum aspirator for 15 minutes, followed by resuspension in 200μl TE. A 
second ethanol precipitation was performed using 20μl 3M NaAc (pH 4.8-5.2) and 400μl cold 
100% ethanol. Samples were mixed and centrifuged at 4º for 5 minutes at 14,000 rpm. 
Supernatant was removed and pellets were washed with 400μl 70% ethanol and centrifuged at 4º 
for 5 minutes at 14,000 rpm. Supernatant was carefully removed by pipetting, and pellets were 
dried in a vacuum aspirator for 15 minutes, followed by resuspension in 25μl TE containing 
2mg/mL RNase. For homozygous lethal genotypes, 50 homozygous first instar larvae derived 
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from sbd/TM6B, P{w+, UbiGFP} stocks were collected based on absence of GFP expression, and 
DNA was prepared as described above. 
The Stubble locus was divided into six regions (Figure 8) for amplification and sequence 
analysis. A series of intron- and exon-specific primers (Table 3) was used to amplify each 
region. Amplification of all regions was conducted using a reaction mix containing 1X reaction 
buffer (10mM Tris-HCl, pH 8.3, 50mM KCl), 10µM 3’-primer, 10µM 5’-primer, 0.8mM dNTPs, 
1.5mM MgCl2 and 1U/rxn Jump-Start Taq polymerase. Stock solutions of reaction buffer (10X), 
MgCl2 (25mM) and Jump-Start Taq were obtained from Invitrogen (Carlsbad, CA). All reactions 
were done in a 20μl volume in 0.5mL thin-walled tubes in the UNOII Biometra Thermocycler. 
Thermal cycler settings used for amplification were the same for all primer pairs and are shown 
in Table 4. Amplification products were run on 1.0% Low EEO agarose, excised and purified 
using the QIAquick Gel Extraction kit (Qiagen, Valencia, CA). DNA concentrations were 
estimated by running 5ul of the purified product on 1.5% Low EEO agarose and comparing band 
intensity to the quantitative Hyperladder II (Bioline USA Inc., Taunton, MA). Purified 
amplification products and primers were sent to the Nevada Genomics Center for sequencing 
using the ABI BigDye Terminator Cycle Sequencing Ready Reaction Kit v3.1 and the ABI3730 
DNA Analyzer. Mutations were verified by sequencing independent PCR products amplified 
from genomic DNA samples originating from different sets of animals of the same mutant 
genotypes. DNA sequence analysis was facilitated by the use of the Lasergene 6 DNA and 
protein analysis software (DNASTAR, Inc., Madison, WI). 
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Table 2. Genotype and regions of all individual mutant stocks used for sequence analysis 
Sb Regions Amplified and Sequenced Genotype 1 2 3 4 5 6 
sbd46/TM6B, Tb Hu e x x x x x x 
w1118/+; iso2/+; iso3/sbd46   x x   
sbd173/TM6B, Tb Hu e x x x x x x 
sbd173/sbd173   x x   
sbd241/TM6B, Tb Hu e x x x x x x 
w1118/+; iso2/+; iso3/sbd241   x x   
sbd258/TM6B, Tb Hu e x x x x x x 
w1118/+; iso2/+; iso3/sbd258   x x  x 
sbd266/TM6B, Tb Hu e x x x x x x 
w1118/+; iso2/+; iso3/sbd266  x x x x  
sbd277/TM6B, Tb Hu e x x x x x x 
w1118/+; iso2/+; iso3/sbd277   x x   
sbdE(br)20/TM6B, Tb Hu e x x x x x x 
sbdE(br)20/sbdE(br)228   x x  x 
sbdE(br)48/TM6B, Tb Hu e x x x x x x 
sbdE(br)48/sbdE(br)228   x x   
sbdE(br)228/TM6B, Tb Hu e x x x x x x 
sbdE(br)448/TM6B, Tb Hu e x x   x x 
sbdE(br)448/sbdE(br)228   x x  x 
sbdE(br)536/TM6B, Tb Hu e x x x x x x 
sbdE(br)536/ sbdE(br)228   x x x  
sbdE(br)623/TM6B, Tb Hu e x x   x x 
sbdE(br)623/sbdE(br)228   x x   
sbdE(br)623/sbdE(br)623   x   x 
sbd1 st ro e ca/ sbd1 st ro e ca x x x x x x 
red sbd201e/TM6B, Tb Hu e x x x x x x 
red sbd201/ red sbd201 x x x x x x 
sbd206 ru cu e ca/ TM6B, Tb Hu e x x x x x x 
sbd206 ru cu e ca/ sbd206 ru cu e ca   x x   
st sbdPNR11e/ TM6B, Tb Hu e x x x x x x 
st sbdPNR11e/ st sbdPNR11e   x x  x 
st sbdVE3e/ TM6B, Tb Hu e x x x x x x 
st sbdVE3e/ st sbdVE3e   x x x  
w1118/ w1118; iso2/iso2; iso3/iso3 (isoline) x x x x x x 
br1/ br1 x x x x x x 
Regions 1–6 refer to the six regions into which the Stubble genetic locus was split for sequencing 
purposes (see Figure 8). A cross (x) denotes successful amplification and sequencing of the 
























Figure 8. Stubble genomic structure and locations of primers used to sequence mutant sbd alleles. 
Sizes of introns and exons are shown to scale and indicated in kilobases. Exons are shown as black boxes with exon number 
indicated below. Features from the cDNA (5’- and 3’-UTR, ATG translation start) are indicated above the exons in which they 
are found. The protease domain is split between the last four exons. Each of the residues forming the catalytic triad (H, D, S) is 
encoded in a separate exon, each indicated above the corresponding exon. The transmembrane domain (TMD), cysteine-
knotted domain (knot) and the first part of the stem are in exon 4. For sequencing purposes, the coding domain of the Stubble 
locus was split into 6 regions. Forward (F) and reverse (R) primers for each region are indicated. Specific primer sequences are 
shown in Table 3. Numbers given with the primers denote the molecular position of its 5’ end. Colored dashes within the 
exons mark the positions of the internal primers in regions 3 (red), 4 (blue), 5 (green), and 6 (yellow). Figure and legend are 











































Table 3. Primers used to amplify and sequence the coding region of the Stubble locus 







Primer Sequence  
(5’→3’) 
5’ Sb Exon 1(1) Region 1F 1 3 11965421 CATTCTCGATGCCATTACAAACATA 
3’ Sb Exon 1(1) Region 1R 1 3 11965703 AACTGGTAGCACACATCGCTGCCTCC 
5’ Sb Region 2 Region 2F 2 4 11966176 AAGTGCGCTTAATTAGTGGTGGACT 
3’ Sb Region 2 Region 2R 2 4 11967038 GATATATTATGCTATCTTTCAAGCCGCTT 
5’ Sb Region 3 Region 3F 3 5,6 11967010 AAGCGGCTTGAAAGATAGCATAATATATCT 
3’ Sb Region 3 Region 3R 3 5,6 11967815 GTTTGTTTCGCTTTCGACATCAAT 
Sb Region 3F seq Region 3IF 3 (internal) 5,6 11967342 GATGCATTGTTAGCATGA 
Sb Region 3R seq Region 3IR 3 (internal) 5,6 11967533 GCAAATTGACGATGCCGG 
5’ Sb Region 4 Region 4F 4 7 11968247 TTCTTAGTTAATGCAGATTTAGCGGC 
3’ Sb Region 4 Region 4R 4 7 11968924 CTAATAAGCTATCATCTTCAATGAGCAAGC 
Sb Region 4F seq Region 4IF 4 (internal) 7 11968602 CTCCAGCTCGAGCACCTC 
Sb Region 4R seq Region 4IR 4 (internal) 7 11968639 GAGTCTTGCTCGATGTGG 
5’ Sb Region 5 Region 5F 5 8,9 11969238 TCAATTTGTGAGGGAATTCGAGATACAGTT 
3’ Sb Region 5 Region 5R 5 8,9 11970028 TAATTGCAATCGCCCCATTTAGAACC 
Sb Region 5F seq Region 5IF 5 (internal) 8,9 11969576 GATCCAGATCGAGCTAAT 
Sb Region 5R seq Region 5IR 5 (internal) 8,9 11969696 GCTCTATGTAGGGCAGCT 
5’ Sb Region 6 Region 6F 6 10,11 11970002 TGGTTCTAAATGGGGCGATTGCAATTA 
3’ Sb Region 6 Region 6R 6 10,11 11970995 TATTGCTCTCGAGCTTTCGCATCGCTAT 
Sb Region 6F seq Region 6IF 6 (internal) 10,11 11970427 CGGAGTCTGTACGAGAAT 
Sb Region 6R seq Region 6IR 6 (internal) 10,11 11970601 TGAAGCTAACTACGCT 
 34
Table 4. Thermal cycling parameters for amplification of sbd alleles 
Segment Cycles Temperature Time 
1 1 94ºC 3 minutes 
2 31 94ºC – Denaturation 1 minute 
  55ºC – Annealing 1 minute 
  72ºC – Extension 1 minute  
3 1 72ºC 15 minutes 
4 1 25ºC 30 minutes 
 
Site-directed mutagenesis 
Site-directed mutagenesis was performed on a full-length Stubble cDNA including 838 
nucleotides of 5’-(UTR) and 523 nucleotides of 3’-(UTR) cloned into the pLitmus29 vector 
(pL29 – Sbc10h7). Site-directed mutagenesis was done using the QuikChange II Site-Directed 
Mutagenesis Kit according the manufacturer’s specifications (Stratagene, La Jolla, CA). Briefly, 
complimentary oligonucleotides containing the desired mutations were designed using 
Stratagene’s web-based QuikChange Primer Design Program 
(http://www.stratagene.com/qcprimerdesign) and ordered through Sigma-Genosys with desalting 
for purification (Sigma-Aldrich Co., The Woodlands, TX) (Table 5). Further purification by 
FPLC or PAGE, as recommended in the QuikChange II protocol, was not performed. 
Mutagenesis reactions were performed by thermal cycling using PfuUltra High-Fidelity DNA 
polymerase. All reactions were done in a 50μl volume in 0.5mL thin-walled tubes in the UNOII 
Biometra Thermocycler. Cycling parameters are listed in Table 6. To make mutations analogous 
to sbd alleles, the oligonucleotides used were H573R which alters histidine 573 to arginine (CAC 
to CGC), P137L which alters proline 137 to leucine (CCA to CTA), and G760S which alters 
glycine 760 to serine (GGC to AGC). To make mutations analogous to human disease-associated 
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mutations, the oligonucleotides used were G760R which alters glycine 760 to arginine (GGC to 
CGC) and S549I which alters serine 549 to isoleucine (AGC to ATC). The serine at 549 was also 
converted to asparagine (AGC to AAC), as found in wild-type human trypsinogen, using 
oligonucleotide S549N. For mutations changing cysteines in the disulfide-knotted domain, 
oligonucleotides Cys2→Ser which alters cysteine 147 to serine (TGC to TCC), Cys3→Ser 
which alters cysteine 153 to serine (TGC to TCC) and Cys5→Ser which alters cysteine 173 to 
serine (TGC to TCC) were used. For mutations which alter each of the two putative start codons, 
the oligonucleotides used were Met1→Leu and Met2→Leu which change methionines 1 and 24, 
respectively, to leucine (ATG to TTG). To alter serine 49 to asparagine (AGC to AAC) and thus 
remove the putative protein kinase C (PKC) phosphorylation site in the intracellular domain, 
oligonucleotide PKC phos S49N was used. Following thermal cycling, mutagenesis reactions 
were digested with the Dpn I endonuclease, specific for methylated and hemimethylated DNA, 
to digest the parental DH5α-derived DNA template and thus select for newly synthesized 
mutation-containing DNA. Upon digestion with Dpn I, mutagenesis reaction DNA was 
transformed into XL1-Blue supercompetent cells. Presence of mutations was verified by 
sequencing the entire Stubble coding region. 
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Table 5. Sequences of oligonucleotides used in site-directed mutagenesis reactions 
Oligonucleotide Name Sequence (5’→3’) 
F H573R TCTCGAGCACCCGCCGTTGCGGTGG 
F P137L GATCAGCCCCAAGCTATGCTCCTTTGGCC 
G760S F GGGATCATCTCCTGGAGCATTGGCTGTGCCG 
G760R F GGGATCATCTCCTGGCGCATTGGCTGTGCCG 
S549I F CGTGGGCGGTAAGATCGCGGCCTTCGGTCG 
S549N F CGTGGGCGGTAAGAACGCGGCCTTCGGTCG 
F Cys2→Ser GTCGAGGGCACCTCCATGTTCGTGTGG 
F Cys3→Ser GTTCGTGTGGGAGTCCATCAAGTCCGAGG 
F Cys5→Ser CATGTTCGGCTCCTCCTGCACGCACAACT 
F Met1→Leu CCGGCACGTTACCGTTGAAGCAGCCAACT 
F Met2→Leu CGGCAGCCACCAAGTTGTGTCCCAAAAGG 
F PKC phos S49N TGCGGCGCGGAACAGGCGCAGTC 
Only forward oligonucleotides and sequences are given. The reverse compliment of each 
forward oligonucleotide sequence gives the corresponding reverse oligonucleotide sequence. 
Point mutations induced by site-directed mutagenesis are shown in bold. 
 
 
Table 6. Cycling parameters for site-directed mutagenesis 
Segment Cycles Temperature Time 
1 1 95ºC 30 seconds 
2 12 95ºC 30 seconds 
  55ºC 1 minute 




Construction of the wild-type hs-Sb+ transgene was described previously (Hammonds 
2002; Bayer 2003). Briefly, a full-length 3.8 kb Stubble cDNA was cloned into the 2.8 kb 
pLitmus29 vector and subsequently into the 8.9 kb pCaSpeR-hs heat-shock-inducible P-element 
transformation vector to allow inducible expression of the transgene under heat-shock control. 
Mutant transgenic constructs were generated by sub-cloning the mutagenized Stubble 
cDNA (described above) from the pLitmus29 vector into pCaSpeR-hs. Mutagenized Stubble 
DNA fragments were removed from pLitmus29 by digestion with BamHI/SpeI and were gel 
purified following electrophoresis in 0.8% SeaPlaque GTG agarose (BioWhittaker Molecular 
Applications, Rockland, ME) in 1X TAE buffer. Bands corresponding to the Stubble mutant 
constructs were excised from the agarose and purified using the QIAquick Gel Extraction Kit 
(Qiagen, Valencia, CA) and cloned into BglII/XbaI-digested pCaSpeR-hs using the Rapid DNA 
Ligation Kit (Roche Diagnostics Corp., Indianapolis, IN). Ligation products were then 
transformed into MAX Efficiency DH5α or TOP10 One Shot competent cells (Invitrogen, 
Carlsbad, CA) according to manufacturer’s specifications with the following exceptions: MAX 
Efficiency competent cells were used in 50μl aliquots and 1μl of undiluted ligation reaction (1-
10 ng) was added for transformation. The resulting hs-Stubble mutant constructs were injected 
into w1118 embryos to generate transgenic lines. 
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CHAPTER THREE: RESULTS – CHARACTERIZATION OF STUBBLE 
MUTANT ALLELES 
At present, the mechanism by which Stubble-mediated extracellular proteolysis 
influences the intracellular Rho1 signaling pathway to control of epithelial morphogenesis is 
poorly understood. In order to better understand the role played by the Stubble protease in 
epithelial morphogenesis, it is necessary to define Stubble action on a mechanistic level. One 
approach to a better understanding of the mechanism of action of Stubble is to determine which 
of the conserved domains found within this protease are necessary for its function. Using 
sequence analysis and genetic interaction assays, I have genetically characterized and identified 
functional domains of sixteen mutant alleles of the Stubble TTSP. 
 
Stubble mutant alleles used in this study 
In an attempt to determine which of the domains contained within the Stubble protease 
are necessary for its function, we conducted sequence analysis of 16 recessive Stubble (sbd) 
mutant alleles having several origins (see Table 1). The six sbdE(br)alleles were generated by 
Ward et al. (2003) through EMS mutagenesis of a stock carrying the br1 allele. Mutagenized 
chromosomes were allowed to undergo free recombination for several generations to remove 
unlinked second-site mutations before being balanced.  
The sbd46, sbd173 sbd177, sbd241, sbd258, sbd266, and sbd277 alleles were produced by EMS 
mutagenesis of w1118 animals carrying isogenic second and third chromosomes (Ruggiero, 2006). 
These alleles were outcrossed after balancing to remove extraneous mutations on the X and 
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second chromosomes; however, this process did not allow free recombination and thus would not 
have removed any second-site EMS-induced mutations carried on the third chromosome. It was 
previously stated that sbd177 no longer carries the sbd mutation (Ruggiero, 2006). This was 
confirmed by generating sbd177/sbd201 trans-heterozygotes. These animals are expected to have 
reduced bristles and malformed legs and wings. In contrast, a wild-type phenotype was observed 
indicating that the sbd177 allele had been lost from the stock. Thus, this allele was excluded from 
further analysis. 
The alleles sbdPNR11 and sbdVE3 were produced by EMS mutagenesis of st e animals and 
sbd206 was produced by EMS mutagenesis of animals of the genotype ru cu ca (Appel, 1992). 
Further information on these alleles is unavailable. Finally, sbd1 is a spontaneous mutation first 
discovered by Sturtevant in 1926 and published by Dobshansky in 1930. 
Sequencing of sbd alleles 
sbdE(br) alleles 
Genomic DNA from sbdE(br)/TM6B, Tb Hu e or sbdE(br)/sbdE(br)228 heterozygotes and the 
br1 progenitor stock for the sbdE(br) alleles was sequenced on both strands through the entire 
protein-coding region. Four differences from either of the published wild-type Stubble sequences 
(Appel et al., 1993; gi (GenBank ID) 158511 and Adams et al., 2000; gi 7300108) were found in 
all six sbdE(br) alleles (Table 7). In an S/T-rich portion of exon 7, the sbdE(br) alleles contain 
sequence variation del2129_2131, an in-frame 3-bp deletion which eliminates the threonine 
residue at amino acid 421, thereby reducing a string of 8 threonines to 7. Also found in the S/T-
rich region of exon 7 is sequence variation 2167A>G, a silent A-to-G single base change at 
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cDNA nucleotide 2167. In exon 9, sequence variation 2752G>T, a silent G-to-T substitution at 
nucleotide 2752, is found in all sbdE(br)alleles. Finally, in exon 10, sequence variation 3037C>T, 
a single base change (C to T) at nucleotide 3037, produces no amino acid change. These four 
variations are also found in the br1 progenitor stock and thus are considered polymorphisms and 
are not attributed to the sbd phenotype observed in animals carrying these alleles. Four 
previously published polymorphisms, all found in exon 6, were also identified in all six sbdE(br) 
alleles and in the progenitor stock (Table 7). These include sequence variations 
del(1727_1744)CAG, a 3-bp CAG in-frame deletion which reduces a string of seven glutamines 
to six between amino acids 287 and 293; 1862C>A, a silent C-to-A point mutation at nucleotide 
1862; 1913A>T, an A-to-T change at nucleotide 1913 that results in a serine-for-threonine 
substitution at amino acid 349 and 1928C>T, a serine-for-proline substitution at amino acid 354 
caused by a single C-to-T base change at nucleotide 1928 (Hammonds and Fristrom, 2006).  
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Table 7. Polymorphisms of the Stubble locus 
Sequence  




1025T>C 4 silent Silent T-to-C single base substitution at nucleotide 1025 sbd1 
1150T>C 4 silent Silent T-to-C single base substitution at nucleotide 1150 sbdVE3, sbdPNR11 
del(1727_1744) 
CAG 6 delQ(287_293) 
In-frame 3-bp deletion of a CAG repeat reduces a string of 7 
glutamines to 6 between amino acids 287 and 293 
sbd46, sbd173, sbd201, sbd241, sbd277, sbdE(br)20, sbdE(br)48, 
sbdE(br)228, sbdE(br)448, sbdE(br)536, sbdE(br)623, sbdVE3, sbdPNR11, 
br1 
1862C>A 6 silent Silent C-to-A single base substitution at nucleotide 1862 
sbd46, sbd173, sbd201, sbd241, sbd277, sbdE(br)20, sbdE(br)48, 
sbdE(br)228, sbdE(br)448, sbdE(br)536, sbdE(br)623, sbdVE3, sbdPNR11, 
br1 
1913A>T 6 T349S A-to-T single base substitution at nucleotide 1913 results in a threonine-to-serine substitution at amino acid 349 
sbd46, sbd173, sbd201, sbd241, sbd277, sbdE(br)20, sbdE(br)48, 
sbdE(br)228, sbdE(br)448, sbdE(br)536, sbdE(br)623, sbdVE3, sbdPNR11, 
br1 
1928C>T 6 P354S C-to-T single base substitution at nucleotide 1928 results in a proline-to-serine substitution at amino acid 354 
sbd46, sbd173, sbd201, sbd241, sbd277, sbdE(br)20, sbdE(br)48, 
sbdE(br)228, sbdE(br)448, sbdE(br)536, sbdE(br)623, sbdVE3, sbdPNR11, 
br1 
del2090_2098 7 delSTT408_410 
In-frame 9-bp deletion from nucleotide 2090 to nucleotide 
2098 removes a serine, threonine, threonine (STT) repeat 
from amino acids 408 to 410 
sbd206, sbd258, sbd266, sbdVE3, sbdPNR11, isoline 
del2129_2131 7 delT421 In-frame 3-bp deletion of ACA reduces a string of 8 threonines to 7 at amino acid 421 in an S/T-rich region  
sbd1, sbd46, sbd173, sbd201, sbd241, sbd277, sbdE(br)20, 
sbdE(br)48, sbdE(br)228, sbdE(br)448, sbdE(br)536, sbdE(br)623, br1 
2167A>G 7 silent Silent A-to-G single base substitution at nucleotide 2167 
sbd1, sbd46, sbd173, sbd201, sbd206, sbd241, sbd258, sbd266, 
sbd277, sbdE(br)20, sbdE(br)48, sbdE(br)228, sbdE(br)448, sbdE(br)536, 
sbdE(br)623, sbdVE3, sbdPNR11, br1, isoline 
2377C>T 7 silent Silent C-to-T single base substitution at nucleotide 2377 sbd258, sbd266, isoline 
2430A>G 7 H521R A-to-G single base substitution at nucleotide 2430 results in a histidine-to-arginine substitution at amino acid 521 sbd
VE3, sbdPNR11 
2752G>T 9 silent Silent G-to-T single base substitution at nucleotide 2752 sbd
46, sbd173, sbd201, sbd241, sbd277, sbdE(br)20, sbdE(br)48, 
sbdE(br)228, sbdE(br)448, sbdE(br)536, sbdE(br)623, br1 
2812G>A 9 silent Silent G-to-A single base substitution at nucleotide 2815 sbd1 
2827G>T 9 silent Silent G-to-T single base substitution at nucleotide 2827 sbd1, sbd206 
3001T>C 10 silent Silent T-to-C single base substitution at nucleotide 3001 sbd258, sbd266, sbdVE3, sbdPNR11, isoline 
3037C>T 10 silent Silent C-to-T single base substitution at nucleotide 3037 sbd
1, sbd46, sbd173, sbd201, sbd206, sbd241, sbd277, sbdE(br)20, 
sbdE(br)48, sbdE(br)228, sbdE(br)448, sbdE(br)536, sbdE(br)623, br1 
a Nucleotide positions are in cDNA numbering corresponding to the published genomic sequence from a y; cn bw sp strain (Adams et al., 2000; gi 7300108). 
b Parentheses indicate uncertainty in the position of the variation. 
c  Isoline refers to w1118; iso2; iso3 stock used as the progenitor for the sbd alleles produced by Ruggiero (2006). 
 42
In addition to the eight polymorphisms identified, four of the six sbdE(br) alleles also 
contain additional changes within the protease domain that are unique to each allele (Table 8; 
Figure 9). Exon 11 of the sbdE(br)20 and sbdE(br)228 alleles contains single amino acid substitutions 
resulting in missense mutations. In sbdE(br)20, a C-to-T change at nucleotide 3141 results in a 
phenylalanine-for-serine substitution (TCC to TTC) at amino acid 758, and in sbdE(br)228, a G-to-
A change at nucleotide 3146 results in an arginine-for-glycine substitution (GGC to AGC) at 
amino acid 760.  
 























sbd266 P137L; T587N directly followed 
by Δnt2630-2922 – causes 
frameshift leading to truncation 
after addition of 14 residues
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Figure 9. Locations of point mutations in sbd alleles.  
Amino acid residue number is shown in the scale at the bottom. Stubble protein domains are shown: CD (cytoplasmic domain) aa 1-
58, TM (transmembrane domain) aa 59-81, knot (disulfide knotted domain) aa 138-173, and serine protease domain from the 
activation cleavage site at aa 543 to the C terminus at aa 787. The residues of the catalytic triad are denoted by solid vertical bars. The 
boundary between exons 10 and 11 is also noted.  
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The allele sbdE(br)448 contains a single amino acid substitution (C to T) at nucleotide 3008 
which replaces the glutamine residue at amino acid position 714 with a stop codon, thus 
truncating the protein 74 residues before its C-terminus and removing the catalytic serine and the 
substrate binding site.  
Finally, the allele sbdE(br)623 contains a 24-bp deletion within the intron separating exons 
10 and 11. The deleted portion of the intron contains the lariat branch point consensus sequence 
CTAAT, in which branch formation occurs at the underlined A (Mount et al., 1992). No 
additional mutations were found in the coding region of the remaining two alleles, sbdE(br)48 and 
sbdE(br)536, thus the mutations leading to the sbd phenotype in these mutants are presumed to be 
of a regulatory nature. 
sbd46, sbd173, sbd241 and sbd277 are all sbd201 alleles 
Four of the putative sbd mutant alleles identified by Ruggiero (2006) in his EMS screen 
are actually sbd201 alleles. Genomic DNA from sbd46, sbd173, sbd241, and sbd277 in homozygous 
condition or in heterozygous condition with the w1118; iso2; iso3 progenitor line, as well as 
genomic DNA from the wild-type w1118; iso2; iso3 progenitor line itself, was sequenced on both 
strands through the entire protein-coding region (see Table 2). In each of these alleles, an 
identical set of four previously published polymorphisms as well as five variations distinct from 
either of the published wild-type sequences were found (Table 7). The four previously published 
polymorphisms found in sbd46, sbd173, sbd241, and sbd277 (del(1727_1744)CAG, 1862C>A, 
1913A>T and 1928C>T) as well as four of the five newly identified differences (del2129_2131, 
2167A>G, 2752G>T and 3037C>T) are identical to the set of polymorphisms described for the 
sbdE(br) and br1 alleles. The br1 stock was also the progenitor for the sbd201 allele used by 
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Ruggerio (2006) to isolate new sbd alleles. The remaining variation is an A-to-G point mutation 
at nucleotide 2586 in exon 8, which results in an amino acid substitution of arginine (CGC) for 
histidine (CAC) at amino acid 573. This change has been attributed by Hammonds and Fristrom 
(2006) to the sbd201 phenotype. The polymorphisms found in the w1118; iso2; iso3 progenitor 
stock used in the screen from which sbd46, sbd173, sbd241, and sbd277 were identified support the 
finding that these alleles are actually alleles of sbd201. The w1118; iso2; iso3 stock (isoline in 
Table 7) contains three polymorphisms not observed in the sbd46, sbd173, sbd241, and 
sbd277alleles. These include sequence variations del2090_2098, a 9-bp in-frame deletion in exon 
7 that results in the deletion of one unit of a tandem repeat of serine, threonine, threonine (STT) 
between amino acids 408 and 410; 2377C>T, a silent C-to-T point mutation at nucleotide 2377 
in exon 7 and 3001T>C, a silent T-to-C point mutation at nucleotide 3001 in exon 10. 
sbd258and sbd266 
Genomic DNA from sbd258 and sbd266/TM6B Tb Hu e or w1118; iso2; iso3/sbd258 and 
sbd266 heterozygotes was sequenced on both strands through the entire protein-coding region (see 
Table 2). These alleles were produced from the w1118; iso2; iso3 progenitor stock, and carry all of 
the polymorphic changes associated with the progenitor (Table 7). In addition, sbd258 contains a 
single base change (G to A) at nucleotide 3132 which results in a glycine-to-glutamic acid amino 
acid substitution at residue 755 (Table 8; Figure 9). 
In addition to the polymorphisms observed in the progenitor stock, sbd266 contains a C-to-
A point mutation at nucleotide 2628, which results in a threonine-to-asparagine (ACC to AAC) 
substitution at residue 587, followed by an out-of-frame 292-bp deletion from nucleotide 2630 to 
nucleotide 2922 that adds 14 incorrect amino acids onto modified residue 587 (Asp) before 
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reading into a stop codon and effectively truncating the protein before any of the catalytic triad 
residues have been added (Table 8; Figure 9). In addition, sbd266 contains a C-to-T point 
mutation at nucleotide 1278, which results in an amino acid substitution of leucine-for-proline at 
amino acid 137. 
sbdPNR11 and sbdVE3 
Genomic DNA from sbdPNR11 and sbdVE3/TM6B, Tb Hu e heterozygotes or sbdPNR11 and 
sbdVE3 homozygotes was sequenced on both strands through the entire protein-coding region (see 
Table 2). The progenitor was not available for sequencing. Nine polymorphisms were identified 
in both alleles, consistent with their origin from a common progenitor (Table 7). These include 
sequence variants 1150T>C, a silent T-to-C point mutation at nucleotide 1150 in exon 2; 
2430A>G, a single A-to-G base change at nucleotide 2430 resulting in an arginine-for-histidine 
substitution at amino acid 521 in exon 7 and del(1727_1744)CAG, 1862C>A, 
1913A>T,1928C>T, del2090-2098, 2167A>G and 3001T>C. In addition to the polymorphic 
variations, sbdPNR11 contains a G-to-A point mutation at nucleotide 3077 which results in the 
substitution of an asparagine (AAT) for an aspartic acid (GAT) at amino acid 737 (Table 8; 
Figure 9). sbdVE3 also contains a sequence variation in addition to the polymorphisms identified. 
This variant is a single C-to-T point mutation at nucleotide 2853 which leads to substitution of 
leucine (CTC) for proline (CCC) at amino acid 662. This proline is a conserved residue in a 
conserved region of the protease domain (Table 8; Figure 9). 
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sbd206 
Genomic DNA from sbd206 ru cu e ca/TM6B, Tb Hu e heterozygotes or sbd206 ru cu e ca 
homozygotes was sequenced on both strands through the entire protein-coding region (see Table 
2). Five differences from either of the published wild-type sequences were found. Four of the 
five differences were polymorphic sequence variations (Table 7): del2090_2098, 2167A>G, 
2827G>T, a silent G-to-T single base change at nucleotide 2827 in exon 9 and 3037C>T. The 
fifth and more significant difference is a C-to-T single base change at nucleotide 2324 which 
results in a nonsense mutation, substituting a stop codon (TAA) for the glutamine (CAA) residue 
at amino acid position 446 in the stem region (Table 8; Figure 9). This mutation results in 
truncation of the Stubble protease in exon 7 prior to the start of the protease domain. 
sbd1 
Genomic DNA from sbd1 st ro e ca homozygous animals was sequenced on both strands 
through the entire protein-coding region. Six differences from either of the published wild-type 
sequences were found (Table 7). Four are polymorphic sequence variations found in other sbd 
alleles (del2129_2131, 2167A>G, 2827G>T and 3037C>T). The remaining two variations are 
both silent changes not found in any of the other sequenced alleles. These include sequence 
variants 1025C>T and 2812G>A (Table 7), a C-to-T single base change at nucleotide 1025 in 
exon 4 and a G-to-A change at nucleotide 2812 in exon 9, respectively. Though these two 
variations have only been identified in one allele, they are most likely polymorphisms because 
they are silent changes. No other changes have been identified in the coding region of sbd1, 
suggesting that the mutation which causes the sbd phenotype may be of a regulatory nature. 
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Second-site noncomplementation analyses between sbd mutations and mutations in Rho1 
pathway members 
Genetic interaction studies of molecularly characterized mutant alleles of a gene can be a 
useful tool to rank the relative severity of different mutations. This, in turn, can establish the 
relative importance of the conserved domains within the protein to protein function and 
potentially link individual domains to different developmental functions.  
In order to genetically characterize the twelve mutant sbd alleles in Table 8, we first 
determined the strength of interaction between these alleles and mutations in Rho1 pathway 
members using second-site noncomplementation (SSNC) analyses. SSNC assays test pairs of 
mutant alleles in double heterozygous condition (i.e. Rho1/+; Sb/+). Strong genetic interactions 
observed in SSNC assays frequently indicate that two genes function in the same signaling 
pathway or act directly on the same developmental process. Previous work in our lab has shown 
that different combinations of Rho1 and Stubble alleles can result in high frequencies of animals 
with leg malformation in SSNC assays (Bayer et al., 2003). For example, the dominant alleles 
Sb63b and Sb70 interact very strongly with Rho1 alleles and a Rho1 deficiency, with malformation 
frequencies ranging from 59-95%. In contrast, the recessive sbd105 deficiency allele shows weak 
interaction with Rho1 alleles and moderate interaction with a Rho1 deficiency. No interactions 
were observed with the recessive sbd1 or sbd201 alleles. In these studies, interactions were defined 
as strong when 50% of animals of the relevant genotype had at least one malformed leg, 
moderate when 25 to 49% of animals show malformation, and weak when 5 to 24% 
malformation is exhibited (Bayer et al., 2003). 
To extend these data, the 12 sbd alleles analyzed in this study were tested for SSNC 
interactions with mutations in Rho1 and zipper, a member of the Rho1 signaling pathway, and 10 
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were tested for dominant interactions with the Rho172O allele. A majority of the SSNC assays 
between sbd mutant alleles and Rho1 mutant alleles were carried out by an undergraduate 
assistant, Stephanie Stallworth, from Daytona Beach Community College participating in the 
NIH Bridges to the Baccalaureate Program who worked under my supervision. 
Genetic interaction data for sbd and Rho1 mutant alleles demonstrate that sbd alleles 
show either weak or no interaction with Rho172O, Rho1J3.8, Rho1E.3.10 and Rho1k02107b (Table 9). 
Leg malformation frequencies range from 0 to 18%, with the majority of Rho1; sbd heterozygous 
combinations exhibiting less than 5% malformation. In combination with the zipper mutant 
zipEbr, three sbd alleles (sbd258, sbdPNR11 and sbd206) exhibit moderate frequencies of 
malformation while the remaining nine alleles exhibit weak or no interaction (Table 9). Because 
all twelve sbd alleles are inviable as homozygotes, the trans-heterozygous combination 
sbd*/sbd1, was used for dominant interaction assays. With the exception of sbdVE3/sbd1, Rho172O 
shows very strong dominant interactions with all ten sbd*/sbd1 trans-heterozygotes tested (Table 
9). However, the background malformation rates for these sbd*/sbd1 combinations range from 59 
to 100% (see sbd/sbd combinations in Table 9) and thus severely limit the usefulness of the data 
obtained from these dominant genetic interaction assays. In contrast, a weak interaction was 
observed between Rho172O and sbdVE3/sbd1 trans- heterozygotes, which have a background 
malformation rate of 0% (see sbdVE3/sbd1 in Table 9). 
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Table 9. Second-site noncomplementation analyses of sbd mutant alleles 
  sbd201e sbd201 sbd1 Rho172O Rho1J3.8 Rho1E3.10 Rho1k02107b zipEbr Rho172O; sbd1 
sbd258 89.1 (46) 97.6 (43) 78.4 (51) 0 (64) 1.1 (92) 2.4 (83) 0 (73) 27.8 (126) 98.5 (66) 
sbd266 100 (6)        semi-lethal 100 (33) 80.7 (57) 0 (93) 0.8 (130) 1.2 (85) 2.2 (91) 21.3 (108) 97.6 (41) 
sbdE(br)20 100 (50) 100 (110) 100 (51) 1.0 (99) 0 (55) 4.2 (142) 7.3 (82) 18.9 (122) 100 (61) 
sbdE(br)48 100 (57) 100 (99) 90.0 (120) 0 (50) 0 (39) 4.4 (135) 2.4 (83) 4.6 (109) 97.5 (79) 
sbdE(br)228 100 (64) 100 (66) 80.9 (42) 1.3 (79) 0.9 (108) 0.8 (113) 2.3 (86) 1.0 (98) 83.3 (60) 
sbdE(br)448 94.1 (51) 100 (86) 97.1 (70) 0 (103) 0 (74) 1.6 (122) 0 (107) 11.2 (107) 100 (77) 
sbdE(br)536 100 (78) 100 (38) 97.3 (74) 2.5 (80) 17.5 (120) 7.0 (113) 8.7 (92) 22.2 (81) 100 (67) 
sbdE(br)623 97.9 (47) 100 (135) 95.4 (65) 0.9 (106) 8.0 (87) 3.8 (133) 3.2 (93) 11.8 (68) 98.8 (83) 
sbdVE3 0 (76) 0 (88) 0 (13) 0 (115) 0 (117) 1.6 (63) 1.9 (104) 0.8 (124) 16.7 (30) 
sbdPNRII 100 (44) 100 (34) 96.4 (28) 0 (122) 1.1 (90) 3.7 (107) 0.9 (116) 35.8 (120) 100 (35) 
sbd206 100 (64) 100 (115) ND 2.3 (129) 4.0 (100) 11.9 (109) 5.4 (93) 33.6 (110) ND 
sbd1 19.8 (116) 45.8 (205) ND 0.7 (143) 1.9 (104) 1.7 (172) 1.6 (122) 6.7 (149) ND 
Animals are either doubly heterozygous, e.g. Rho172O/+; sbd258/+, or trans-heterozygous, e.g. sbd258/sbd201 e. The numbers shown 
indicate the percentage of animals with malformed legs, with the total number of animals of the indicated genotype scored shown in 
parentheses. ND, not determined. 
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sbd 258 89.6 ± 1.7 100 NA
sbd 266 4.0 ± 0.4 100 NA
sbd PNR11 8.0 ± 1.9 100 NA
sbd VE3 29.1 ± 4.1 100 NA
sbd 206 6.8 ± 0.1 100 NA





Pupal     
lethalityc
Lethal-phase analysis of sbd mutant alleles 
To characterize the effects of each mutation on Stubble protease function, lethal-phase 
studies were conducted. These experiments were done in the same manner as described by Ward 
et al. (2003) to characterize the sbdE(br) alleles (see Methods). These experiments reveal that 
sbd258 exhibits predominantly embryonic lethality, with only 10% of embryos hatching (Table 
10). Those animals that do hatch die as early first instar larvae. Four of the six mutants tested, 
sbd266, sbdPNR11, sbdVE3, and sbd206, are predominantly larval lethal. The remaining allele, sbd1, 
shows broad stage-specific lethality with ~45% viable adults. 
 












a Mean ± SE of embryonic lethality from three independent experiments. Embryonic lethality 
was calculated as (number of dead embryos/total number of mutant embryos) x 100. 
b Mean ± SE of larval lethality from three independent experiments. Mutant larvae were picked 
as newly hatched first instar larvae. Larval lethality was calculated as [(total number of mutant 
larvae – number of pupae)/total number of mutant larvae] x 100. 
c Mean ± SE of pupal lethality from three independent experiments. Pupal lethality was 
determined by allowing those larvae from the larval lethality assay that pupariated to eclose. 
Adults were counted and pupal lethality was calculated as [(total number of pupae – number of 
adults)/total number of pupae] x 100. NA, not applicable.  
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Experiments in progress 
Classification of sbd mutant alleles. 
In 1932, Muller developed a naming system to classify mutations based on their behavior 
in various genetic situations (Muller, 1932). He coined the terms amorph, hypomorph, 
hypermorph, antimorph and neomorph to define the genetic behavior of various classes of alleles 
he observed. In Muller’s terminology, an amorphic mutation results in a complete loss of gene 
function while a hypomorphic mutation causes a partial loss of gene function. Hypermorphic, 
antimorphic (also called dominant negative) and neomorphic mutations result in a gain of gene 
function. A hypermorph causes an increase in normal gene activity (e.g. transcription), an 
antipmorph is a dominant mutation that acts antagonistically to normal gene activity, and a 
neomorph is a mutation that results in a gain of novel gene activity. If the behavioral 
classification of an allele can be determined, it can prove useful in the interpretation of classical 
and molecular genetic data. 
To classify the nine non-regulatory mutations as well as the three putative regulatory 
mutations in our sbd alleles (see Table 8) as amorphic, hypermorphic or gain-of-function, the 
developmental progress and lethal phase of sbd homozygotes was monitored and compared with 
that of trans-heterozygous sbd*/Df(3R)sbd105 animals. The Df(3R)sbd105 allele contains a 
deficiency which removes the entire Stubble locus. In trans-heterozygous condition with a 
deficiency, an amorphic mutant should exhibit identical developmental progress and lethal phase 
as the amorphic homozygote since both genotypes result in complete loss of gene function. A 
hypomorphic mutant should exhibit a more severe phenotype over a deficiency than as a 
homozygote. Hypermorphic mutations should exhibit a less severe phenotype over a deficiency 
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than as a homozygote. The phenotype of dominant negative homozygous mutations compared to 
dominant negative over a deficiency is hard to predict; however, the severity of phenotype of a 
dominant negative can be reduced by over-expressing the wild-type protein. In contrast, the 
phenotype of a hypermorphic mutation is expected to become worse if the the wild-type protein 
is over-expressed. Finally, the phenotype of neomorphic mutations as homozygotes or over a 
deficiency is expected to be similar; however, over-expression of wild-type protein will have no 
effect on the phenotype. 
At present, only sbd258, sbdPNR11, sbd206, and sbdE(br)228 have been tested. All other alleles 
(see Table 8) remain to be analyzed. As homozygotes, sbd258 animals are predominantly 
embryonic lethal, whereas sbdPNR11, sbd206, and sbdE(br)228 animals exhibit predominantly larval 
lethality (see Table 10). As trans-heterozygotes with Df(3R)sbd105, all four alleles show 
improved development with at least half of the animals surviving to adulthood, suggesting that 
all are associated with gain-of-function mutations.  
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CHAPTER FOUR: RESULTS – SCREEN FOR G PROTEIN-COUPLED 
RECEPTORS THAT INTERACT WITH STUBBLE TO CONTROL LEG 
DEVELOPMENT 
It has been proposed that the Stubble protease operates through an “outside-in” signaling 
mechanism during leg development to either act in parallel with or directly regulate Rho1 
signaling. Four vertebrate TTSPs have also been shown to operate via an apparent outside-in 
signaling mechanism using the GPCR PAR-2. In addition, GPCRs are known to be major 
upstream regulators of vertebrate Rho signaling through activation of heterotrimeric G proteins. 
Because GPCRs have been linked to both extracellular proteolytic activity and intracellular Rho 
signaling, I asked if the known non-odorant and non-gustatory G protein-coupled receptors 
within the Drosophila genome interact genetically with Stubble in the control of leg imaginal 
disc morphogenesis. Though it is not inconceivable that an odorant or gustatory receptor could 
link Stubble proteolytic activity with Rho1 signaling in epithelial development, these receptor 
types were excluded based on their known involvement in the nervous system. 
Excluding the 119 gustatory and odorant receptors, 147 genes encoding G protein-
coupled receptors have been identified in the Drosophila genome. Four of these have not been 
mapped to the genome sequence and thus were also excluded. To screen for G-protein-coupled 
receptors potentially involved in leg morphogenesis, SSNC assays were performed by mating 
heterozygous Stubble mutant animals (i.e., red Sb63be/TM6B, Tb Hu e) with heterozygous or 
homozygous animals carrying a deficiency uncovering the GPCR, or a lethal transposable 
element insertion or mutation in the GPCR. Resulting adults of the doubly mutant heterozygous 
class, e.g., GPCR/+; red Sb63be/+, were scored for frequency of leg malformation. Stubble 
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mutant animals exhibit a background malformation rate of ~2%. A minimum increase in 
malformation rate of 20-fold above background is considered significant, and thus only crosses 
producing greater than 40% malformation in the doubly heterozygous F1 class were deemed 
significant. At present, 98 of the 147 GPCR-encoding genes have been tested for genetic 
interactions with Stubble in a total of 155 individual assays. A majority of this work was done by 
Nikette Benjamin, an undergraduate research assistant who worked under my supervision. From 
this screen, we identified 4 interacting chromosomal regions which collectively uncover 8 
GPCRs (Table 11). A list of all deficiencies and mutations tested is given in Appendix 1. 
 
Table 11. GPCR deficiencies showing strong interactions with Sb63b 
Deficiency  Region Uncovered  GPCRs Uncovered  % mlf with Sb63b  
Df(2L)Exel7027  26F6-27B1  GRHR  57.1 (28) 
Df(2R)Exel6068 56A1-56B5 5-HT1A, 5-HT1B 34.5a (29) 
Df(3L)Exel6084  61B2-61C1  mthl9, mthl10, mthl14  80.4 (92) 
Df(3R)red-P52  88A4-88B2  CG9918, DopR  87.5 (40)  
a The percent malformation for Df(2R)Exel6068/+; red Sb63b e/+ animals was less than 40%; 
however, this deficiency was kept for further evaluation due to the low number of double 
heterozygote animals produced in the primary assay. 
 
Df(2L)Exel7027 
The first interacting region, 26F6-27B1, is uncovered by the deficiency Df(2L)Exel7027. 
This region contains 21 genes, including the GPCR gonadotropin-releasing hormone receptor 
(GRHR). Doubly heterozygous Df(2L)Exel7027/+; red Sb63b e/+ animals exhibit 57% leg 
malformation, suggesting that one or more of the 21 genes deleted on the deficiency 
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chromosome is involved in leg disc morphogenesis. Because a high frequency of malformation 
was obtained for the deficiency in combination with Sb63b, we performed a series of follow-up 
experiments to verify the initial genetic interaction, and reduce the size of the interacting region 
carrying the interacting gene(s) (Table 12). To assay for consistent interaction between the 
deficiency allele and the Stubble locus, Df(2L)Exel7027 animals were crossed to animals 
carrying Sb70, a second mutant allele of Stubble. Animals of the doubly heterozygous 
Df(2L)Exel7027/+; Sb70/+ class exhibit 61% leg malformation, consistent with the malformation 
frequency obtained with Sb63b. Deficiency animals were also mated with animals carrying br1, a 
mutant allele of broad. The broad locus encodes an ecdysone-inducible gene which interacts 
genetically with the Stubble locus (Beaton et al., 1988). The br1/Y; Df(2L)Exel7027/+ male 
progeny from this cross exhibit only 6% malformation indicating that Df(2L)Exel7027 does not 
interact dominantly with br1. This low malformation rate does not necessarily exclude the 
(unidentified) interacting gene from involvement in the ecdysone hierarchy. Previous experience 
in our laboratory has shown that genetic interactions can be very allele specific where loss-of-
function alleles do not always show interactions while gain-of-function alleles of the same gene 
may. For example, null alleles of the non-muscle myosin heavy chain gene, zipper, are non-
interactive in SSNC assays, whereas weak gain-of-function alleles of this gene, e.g. zipEbr, are 
interactive. A reasonable explanation for these observations is that one functional copy of the 
zipper gene product is sufficient for proper development. However, because the zipper protein 
functions as a dimer, the presence of a weak gain-of-function allele results in a high proportion 
of unproductive dimers and interferes with the function of the wild-type gene. Further assays 
with mutants of Rho1 and Notopleural (Np), a genetic locus that potentially cooperates with the 
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Stubble locus in regulation of bristle formation and leg development (Ruggerio, 2006), are 
pending. 
 
Table 12. Second-site noncomplementation analyses with Stubble interactors 
Deficiency Sb70 Rho1E3.10 Rho1J3.8 Np2 Np125A br1/Y 
Df(2L)Exel7027 61.3 (106) ND ND ND ND 6.3 (32) 
Df(2R)Exel6068 58.4 (89) ND ND ND ND 38.6 (44) 
Df(3L)Exel6084 95.6 (68) 2.3 (88) 5.6 (72) 6.2 (97) 5.0 (140) 33.3 (39) 
Df(3R)red-P52 ND ND ND 79.4 (63) 80.0 (55) ND 
Animals are doubly heterozygous, e.g. Rho1E3.10/+; Df(3R)red-P52/+, or + Sb70/Df(3R)red-P52 
+. The numbers shown indicate the percentage of animals with malformed legs, with the total 
number of animals of the indicated genotype scored shown in parentheses. ND, not determined. 
 
Df(2R)Exel6068 
A second genomic region showing interaction with Sb63b is 56A1-56B5. This region 
contains 16 genes, including the GPCRs 5-HT1A and 5-HT1B, and is uncovered by 
Df(2R)Exel6068. Doubly heterozygous animals, i.e., Df(2R)Exel6068/+; red Sb63b e/+, exhibit 
35% malformation (Table 11). This malformation frequency is below the 40% threshold 
considered significant, but due to the low number of progeny produced in the primary cross, 
secondary SSNC assays were done to determine the reliability of the data (Table 12). Animals of 
the genotype Df(2R)Exel6068/CyO were crossed to Sb70/TM6B, Tb Hu e animals. The resulting 
doubly heterozygous Df(2R)Exel6068/+; Sb70/+ class, which contained three times as many 
animals as the class of interest in the original screen, exhibits 58% leg malformation. Further 
evidence that Df(2R)Exel6068 uncovers an interacting gene comes from the moderate interaction 
observed for Df(2R)Exel6068 in the presence of br1. Thirty-nine percent of br1/Y; 
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Df(2R)Exel6068/+ animals exhibit leg malformation, suggesting that an interacting gene(s) 
contained within the region uncovered by Df(2R)Exel6068 is involved in ecdysone signaling. It 
will be interesting to determine the strength of genetic interactions between Df(2R)Exel6068 and 
Rho1 and Np alleles. 
Df(3L)Exel6084 
A third deficiency which shows very strong interaction with Sb63b is Df(3L)Exel6084. 
This stock carries a deletion of genomic region 61B2-61C1, which completely removes 43 
genes, including the GPCRs methuselah-like (mthl) 9, mthl10 and mthl14. Mutant 
Df(3L)Exel6084 animals exhibit 80% leg malformation in trans-heterozygous condition with 
Sb63b(Table 11). The high frequency of malformation observed implies a very strong interaction 
between Stubble and a gene(s) within the deleted region, thus a number of secondary 
experiments have been done to determine which deleted gene product interacts with Stubble and 
to further define the role of the deleted region in leg development (Table 12). 
To verify the strength of the interaction observed between the deficiency chromosome 
and Stubble, Df(3L)Exel6084 animals were crossed to mutant Sb70 animals. The trans-
heterozygous Df(3L)Exel6084/Sb70 animals exhibit 96% leg malformation, consistent with the 
data obtained with Sb63b. To test for further interaction with ecdysone-responsive genes, 
Df(3L)Exel6084 animals were crossed to br1 mutants. From the br1 assay, a moderate 
malformation frequency of 33% was observed for progeny of the genotype br1/Y; 
Df(3L)Exel6084/+. Interestingly, only very weak interactions were observed between 
Df(3L)Exel6084 and Rho1E3.10 or Rho1J3.8 (2% and 6%, respectively) or between Df(3L)Exel6084 
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and the zipper allele, zipEbr (12%; data not shown). Similarly, weak interactions were observed 
for Df(3L)Exel6084 in combination with the Notopleural alleles Np125A and Np2 (5% and 6%, 
respectively). Collectively, these data raise the possibility that the interacting gene(s) uncovered 
by Df(3L)Exel6084 may cooperate with Stubble to regulate leg development through a pathway 
independent of Notopleural or Rho1. 
In an attempt to identify the interacting gene(s) uncovered by Df(3L)Exel6084, nine 
additional deficiencies which overlap the 61B2-61C1 genomic region were tested for SSNC with 
Sb63b (Table 13; Figure 10). Of the nine deficiencies tested, two, Df(3L)BSC128 and 
Df(3L)Exel9057, show significant interactions (79% and 51%, respectively) in combination with 
Sb63b. This suggests that there are two interacting genes within the deleted region.  
Several inconsistencies are apparent from the overlapping deficiency map shown in 
Figure 10. Based on the published breakpoints, Df(3L)ED201, which shows no interaction with 
Sb63b, encompasses both strongly interacting deficiencies as well as the original deficiency line 
Df(3L)Exel6084. In addition, Df(3L)BSC126, which displays moderate interaction in 
combination with Sb63b (Table 13), completely overlaps with the strong interactor Df(3L)Exel 
9057. It has been our experience that the published breakpoints for many deficiencies are 
unreliable, thus we are currently defining the molecular breakpoints of the deficiencies shown in 
Figure 10 using molecularly defined lethal P-element insertions and mutations to assay for non-
complementation when in combination with the various deficiencies. The deficiencies 
overlapping Df(3L)Exel6084 are also being mated to one another to determine whether the 
genomic overlaps are real (Table 14). Though only a few of these experiments have been 
completed, several informative pieces of data have been obtained. For example, 
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Df(3L)BSC128/Df(3L)7C animals are viable, indicating that the left boundary of Df(3L)7C does 
not likely extend as far to the left as indicated by the dashed line (region of uncertainty) in 
Figure10. The Df(3L)ED201/Df(3L)7C combination, however, is lethal, indicating that, though 
the left breakpoint of Df(3L)7C may be much farther to the right than indicated, there is still 
some region of overlap between Df(3L)7C and Df(3L)ED201. Df(3L)ED201 also exhibits 
lethality in combination with Df(3L)BSC128. This confirms the predicted overlap between these 
two deficiencies but does not explain how Df(3L)BSC128 exhibits strong interaction with Sb63b 
while Df(3L)ED201 shows no interaction with the same allele. Additional assays are necessary to 
resolve this issue. As predicted by their molecular breakpoints, none of the deficiencies 
Df(3L)BSC121, Df(3L)BSC128 or Df(3L)BSC125 is lethal in combination with Df(3L)Exel9057. 
These data confirm that there is likely no region of overlap between the these BSC deficiency 
chromosomes and Df(3L)Exel9057. In contrast, Df(3L)Exel9057 shows partial lethality in 
combination with Df(3L)BSC126. Interestingly, the few animals that survive to adulthood show 
no malformation. This is consistent with the semi-lethal phenotype of homozygous 
Df(3L)Exel9057 animals. 
 
Table 13. Deficiencies overlapping Df(3L)Exel6084 
Deficiency  Genomic Region Uncovered % mlf with Sb63b
Df(3L)BSC126 61B3-61C1 26.6  
Df(3L)BSC125 61B3 25.0 
Df(3L)BSC128 61B2 79.4 
Df(3L)Exel6083 61A6-61B2 3.2 
Df(3L)Exel9057 61C1 51.2 
Df(3L)ED201 61B1-61C1 0.0 
Df(3L)7C 61B2-61C 5.3 
Df(3L)BSC121 61B2 35.8 




















Figure 10. Deletion map showing breakpoints for Df(3L)Exel6084 and overlapping deficiencies.  
The scale along the top shows the genomic region. Positions of the 3 GPCRs uncovered by Df(3L)Exel6084 are denoted with 
arrows. Positions of molecularly mapped lethal P-element insertions and mutations are denoted by arrowheads. Molecular 
breakpoints have not been determined for 7C, thus the extent of the deleted region is unknown. The area of uncertainty is 
indicated with dashed lines. 
















Table 14. SSNC analyses of deletions overlapping Df(3L)Exel6084 
  Df(3L)7C Df(3L)Exel6084 Df(3L)ED201  Df(3L)BSC128 Df(3L)Exel9057 Df(3L)BSC125 Df(3L)BSC126 
Df(3L)Exel6084 ND       
Df(3L)ED201 lethal ND      
Df(3L)BSC128 0 (40) ND lethal     
Df(3L)Exel9057 ND ND ND 0 (141)    
Df(3L)BSC125 ND ND ND ND 0 (19)   
Df(3L)BSC126 ND ND ND ND semi-lethal ND  
Df(3L)BSC121 ND ND ND ND 2.2 (45) ND ND 
Animals are trans-heterozygous, e.g., Df(3L)Exel6084/ Df(3L)7C. The numbers shown indicate the percentage of animals with 
malformed legs, with the total number of animals of the indicated genotype scored shown in parentheses. ND, not determined. 
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Df(3R)red-P52 
The fourth and final genomic region showing strong interaction with Stubble is 88A4-
88B2, which is uncovered by Df(3R)red-P52 (Table 11). This region contains at least 43 genes, 
including the GPCRs CG9918 and Dopamine Receptor (DopR). Animals of the Df(3R)red-
P52/red Sb63b e class exhibit 88% leg malformation. Interestingly, the malformation observed in 
this class is not typical of the malformation phenotype normally observed (see Figure 6). All 
malformed Df(3R)red-P52/red Sb63b e animals have at least one excessively bowed tibia on the 
third set of legs that twists slightly to the outside of the body such that it crosses the femur when 
the legs are folded. The femurs, however, are all of the wild-type length and shape. Due to its 
subtle nature, this phenotype would generally be scored as wild-type when seen in an individual 
animal. However, since almost 90% of animals of the genotype Df(3R)red-P52/red Sb63b e 
exhibit this phenotype, the deficiency was considered worthy of additional experiments. 
In an attempt to further define the nature of the interaction observed between Df(3R)red-
P52 and the Stubble locus, deficiency animals were crossed to Np125A and Np2 (Table 12). As 
with Sb63b, Df(3R)red-P52 shows very strong interaction in combination with both Np125A and 
Np2, yielding malformation frequencies of 80% and 79%, respectively. The phenotype seen in 
combination with Notopleural mutants is the same as that observed in Df(3R)red-P52/red Sb63b e 
animals. Further SSNC and dominant interaction analyses will be performed between Df(3R)red-
P52 and Sb70, Rho1E3.10, Rho1J3.8 and br1. 
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CHAPTER FIVE: DISCUSSION 
To understand the role that TTSPs play in development, homeostasis and disease 
progression, it is necessary to understand their mechanism of action. The Stubble protease serves 
as an excellent model in which to study the mechanism by which TTSPs interact with 
intracellular signaling pathways to regulate developmental processes. In this study, I have 
attempted to develop a greater understanding of the mechanism of action of the Stubble TTSP 
using two distinct approaches. First, I sequenced 12 mutant alleles of Stubble to determine which 
of the conserved domains contained within the protease are necessary for proper function of 
Stubble. Most of the mutations identified are located within or directly effect the protease 
domain, indicating that this domain is necessary for function. One mutation was found outside of 
the protease domain, but the relevance of this mutation to protease function has not been 
established. Second, I performed a genetic interaction screen of the non-gustatory, non-odorant 
GPCRs within the Drosophila genome in an attempt to find a target of the Stubble protease. 
Though no individual targets have been identified to date, a few promising leads have been 
obtained which are currently being investigated further. 
Sequencing of Stubble mutant alleles 
i.) Identification of four sbd alleles as sbd201 
In this study I show that four of the putative sbd alleles (sbd46, sbd173, sbd241 and sbd277) 
isolated by Ruggiero (2006) are actually sbd201 alleles. An overview of the strategy used by 
Ruggiero (2006) to identify enhancers of the recessive sbd201 leg and bristle phenotypes is shown 
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in Figure 11. In the strategy, a tester stock with the genotype Pm/CyO; red sbd201 e/TM6B, Tb Hu 
e was mated to mutagenized animals (G1 cross in Figure 11). It is possible that during the 
subsequent recovery and isolation of the enhancer chromosome, a recombined sbd201 
chromosome lacking the recessive ebony marker could have been recovered rather than the 
enhancer of sbd chromosome. As a consequence, at one or more points during this screen, the 
sbd*/sbd201 class may have been confused with the sbd201/sbd201 class resulting in isolation of the 
sbd201 allele rather than the sbd* allele. The sequence data support the possibility that the tester 
and enhancer chromosomes were exchanged: sbd201 was produced in an earlier EMS screen 
which used br1 as the progenitor stock (Beaton et al., 1988), and the polymorphisms found in 
sbd46, sbd173, sbd241, and sbd277 are identical to those found in br1 and sbd201. The data presented 
here differ from the findings of Hammonds and Fristrom (2006) in that both sbd201 and its br1 
progenitor lack the del2090_2098 sequence variant in exon 7. This deletion was observed in the 
w1118; iso2; iso3 progenitor stock used in Ruggiero’s EMS screen but was not found in the sbd201 
or br1 stocks that I sequenced. 
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Figure 11. A schematic overview of the Ruggiero sbd201 enhancer screen strategy. 
Taken from Ruggiero, 2006. 
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ii.) Effects of protease domain mutations on Stubble activity 
Of the 12 sbd alleles sequenced, 8 carried specific mutations in the protein coding region. 
In every case, mutations that are very likely to affect Stubble proteolytic function (see below) 
were observed. In 2 cases additional mutations outside the proteolytic domain, were also 
identified.  
Upon activation of trypsin-like serine proteases, approximately 85% of the structures of 
the protease domain remain organized identically and in the same conformation in the active 
peptide as they were in the inactive zymogen. The remaining 15% of the protease domain (the 
activation domain), which includes the substrate binding site and the oxyanion hole (see below), 
undergoes a series of conformational changes. The folding of the activation domain is facilitated 
by four conserved glycine residues which serve as hinges around which activation domain 
segments move to form the active enzyme. Upon folding, the activation domain becomes ordered 
while forming a closed domain that is stabilized by a salt bridge between the now-liberated N-
terminus of the activation cleavage site isoleucine, Ile16 (Ile544 in Stubble), and aspartic acid 
194 (Asp737 in Stubble; Gombos et al., 2008) (Note: When giving coordinates for amino acid 
residues in the protease domain, the chymotrypsinogen numbering system will be used unless 
otherwise noted). Formation of the Ile16-Asp194 salt bridge is also necessary to form a structural 
linkage between the catalytic triad and the oxyanion hole during substrate binding (Figure 12). 
The oxyanion hole is formed by the backbone amide NHs of Gly193 (Stubble Gly736) and 
catalytic Ser195 (Stubble Ser738) and forms a pocket of positive charge that works to stabilize 
the negatively charged oxyanion of an intermediate structure during substrate binding (Matthews 
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et al., 1975). Incomplete folding of the activation domain in the zymogen results in inactivity of 
the protease. 
The main chain residues 214-216 (Stubble 758-760) make up the substrate binding site 
and form an antiparallel beta sheet with the backbone P1-P3 residues of the substrate (Figure 13). 
Hydrogen bonds form between the carbonyl oxygen of Ser214 (Stubble Ser758) and the amide 
NH of the P1 residue, the amide NH of Trp215 (Stubble Trp759) and the carbonyl oxygen of P2 
and the carbonyl of Gly216 (Stubble Gly760) and the amide NH of P3. These interactions are 
essential for efficient proteolysis of the substrate. In addition to the primary substrate binding 
site, residues 214-216 form a portion of one wall of the S1 subsite (specificity pocket; Figure 
14), and the carbonyl of Ser214 forms a hydrogen bond with the catalytic histidine. These 
structural interactions form a connection between the substrate binding site, the S1 site, and the 









Figure 12. Structure of chymotrypsin showing positioning of the oxyanion hole. 
The oxyanion hole is structurally linked to the Ile16-Asp194 (Stubble Ile544-Asp737) salt bridge 
and the catalytic triad residues His57, Asp102 and Ser195 (Stubble His590, Asp640 and Ser738) 














Figure 13. Mechanism of substrate binding for serine proteases. 
Catalytic groups of chymotrypsin-fold serine protease are depicted interacting with a substrate at 
its P1 site (substrates are hydrolyzed at the P1-P1’ bond). Five enzyme-substrate hydrogen bonds 
at positions P1 and P3, including those involving Ser214 and Gly216 (Ser758 and Gly760 in 
Stubble), are shown in addition to hydrogen bonds among members of the catalytic triad. The 
interaction of amide NH of Trp215 (Stubble Trp759) with the carbonyl oxygen of the P2 residue 























Figure 14. Schematic diagram of the S1 subsite of chymotrypsin interacting with a substrate. 
The S1 subsite is composed of three walls formed by residues 189-192, 214-216 and 224-228 
(732-735, 758-760 and 768-772 in Stubble). Residues 214, 224 and 225 (Stubble 758, 768 and 
769) are not labeled. Substrate specificity is usually conferred by amino acids at residues 189, 
216 and 226 (Stubble residues 732, 760 and 770). Carbon atoms are shown in gray, oxygen in 
red, sulfur in yellow and nitrogen in blue. The catalytic serine is boxed. The substrate is shown in 
green. Taken from Berg, Tymoczko, and Stryer, 2007. 
 
 
Several of the mutations found in the 12 sbd alleles analyzed (see Table 8) affect 
structures involved in protease activation, folding and substrate binding as discussed above. 
Given the importance of proper maintenance of these structures on protease function, these 
mutations are likely to have substantial effects on Stubble proteolytic activity. For example, 
Glycine 760, which functions as one of the four glycine hinge residues necessary for proper 
activation domain folding, is substituted for a serine residue in sbdE(br)228. It has been proposed 
that restriction of flexibility around these hinges by amino acid substitution may lead to a 
zymogen-like conformation in the active protease (Gombos et al., 2008). The necessity of 
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functional glycine hinges for enzymatic activity is exemplified by the finding that substitution of 
any of the hinge glycines in blood coagulation-related serine protease factors VII, IX and X leads 
to bleeding disorders (Bernardi et al., 1996; Giannelli et al., 1994; Uprichard et al., 2002; Wulff 
et al., 2000). 
Both sbdE(br)20 and sbdE(br)228 contain mutations in highly conserved residues that directly 
interact with the substrate during binding (Huber and Bode, 1978). In the allele sbdE(br)20, serine 
758, which is involved in direct binding with the P1 residue of the substrate, is altered to a 
phenylalanine. In sbdE(br)228, glycine 760 is altered to a serine residue. Gly760 is involved in 
direct binding with the P3 residue of the substrate. Both of these changes are nonconservative. In 
the case of S758F, a polar residue is replaced with a nonpolar residue, and a nonpolar residue is 
replaced with a polar residue as a result of the G760S mutation. A shift between nonpolar and 
polar amino acids in each case could result in misfolding of the substrate binding pocket. 
Nonpolar amino acids tend to face the interior of the folded molecule while polar residues tend to 
cluster to the surface where interactions with water molecules in the surrounding environment 
are maximized. Thus the substitution of Ser758 for phenylalanine in sbdE(br)20 as well as the 
substitution of Gly760 for serine in sbdE(br)228 potentially interfere with normal Stubble function 
be inhibiting substrate binding and disrupting intramolecular interactions between various 
regions of the catalytic domain. 
sbdPNR11 contains a point mutation which results in the substitution of aspartic acid 737 
for asparagine. Aspartic acid 737 is involved in the formation of the Ile544-Asp737 salt bridge 
(Ile16-Asp194 in chymotrypsinogen numbering). This salt bridge stabilizes the folded activation 
domain and is necessary for linkage of the catalytic triad with the oxyanion hole during substrate 
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binding (see Figure 12). Disruption of this salt bridge due to the substitution of asparagine for 
aspartic acid at amino acid 737 is predicted to inhibit proper stabilization of the active molecule 
and lead to a zymogen-like conformation with greatly diminished substrate binding capabilities. 
The sbd258 mutant allele contains a single amino acid substitution, G755E, in the protease 
domain that alters the normal activity of the Stubble protein. Glycine 755 is a highly conserved 
residue in a highly conserved region of the protease domain. This glycine residue is located 3 
residues amino-terminal to the polypeptide binding site but is not known to be directly involved 
in substrate binding. The substitution of a nonpolar, hydrophobic glycine residue for a polar, 
hydrophilic glutamic acid residue in such close proximity to the substrate binding pocket could 
inhibit proper folding of the substrate binding pocket and thus interfere with the ability of the 
Stubble protease to bind and cleave substrates properly. 
In addition to the specific mutations found within the various structures of the protease 
domain, several sbd alleles contain truncations which remove a portion or the whole of the 
protease domain. sbd206 and sbdE(br)448 both contain single point mutations which result in the 
change of a glutamine residue for a stop codon. The sbd206 allele contains a nonsense mutation at 
residue 445 in the stem of the Stubble protein (see Figure 9). This substitution leads to truncation 
of the protein within the stem, completely eliminating the protease domain. The sbdE(br)448 allele 
contains a nonsense mutation at residue 714, twenty-four residues N-terminal to the catalytic 
triad serine residue in the protease domain (see Figure 9). This substitution results in a truncation 
which removes the catalytic serine as well as the substrate binding domain. A third allele, sbd266, 
also causes a truncation of the protein, but it does not involve a nonsense mutation. This allele 
contains a threonine-to-asparagine amino acid substitution at residue 587 (see Figure 9) which is 
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directly followed by an out-of-frame 292-bp deletion. The frameshift results in the addition of 14 
incorrect residues onto the modified asparagine before reading into a stop codon. This 
deletion/frameshift mutation effectively removes the majority of the protease domain, including 
all three residues of the catalytic triad and the substrate binding pocket. 
In addition to an amino acid substitution and an out-of-frame deletion, sbd266 also 
contains an amino acid substitution within the Stubble stem region. The proline residue at 
position 137 is altered to a leucine. This proline residue directly precedes the disulfide-knotted 
domain, and a substitution could potentially cause improper folding and disruption of the 
flanking disulfide-knotted domain. As this allele also contains a deletion that removes the 
majority of the protease domain, it is unclear to what extent the P137L amino acid substitution 
contributes to the sbd266 phenotype. 
The sbdE(br)623 allele contains a 24-bp deletion in the intron separating exons 10 and 11 in 
the proteolytic domain (see Table 8 and Figure 9). The deleted portion of the intron contains the 
lariat branch point consensus sequence CTAAT, in which branch formation occurs at the 
underlined A (Mount et al., 1992; Figure 15). Splicing events begin with assembly of the 
spliceosome onto the pre-mRNA by binding sequences located at the 5’ and 3’ ends of the intron 
(reviewed in Graveley, 2004). This assembly is initiated by association of the U1 small nuclear 
ribonucleoprotein (snRNP) with the 5’ splice site, the branch-point-binding-protein/SF1 with the 
branch point, and the U2 snRNP auxiliary factor (U2AF) with the pyrimidine tract. Stable 
association of the U2 snRNP at the branch point and splice-site pairing then occurs upon ATP 
hydrolysis. Few mutations of branch point sequences have been identified, but those that have 
been found have resulted in cryptic splicing (Rosenthal et al., 1992; Brand et al., 1996; Fujimaru 
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Exon 10 Exon 11 
IVS 10 
GTGAGATGCCGGATAAAGCAAACCTACGAGATATATGCTAATAAACATTTTGCAG
et al., 1998), intron retention (Kuivenhoven et al., 1996) and exon skipping (Putman et al., 1997; 
Burrows et al., 1998; Hamlington et al., 2000). Therefore, the splicing defect in sbdE(br)623 is 
likely to alter the C-terminus of the protease domain. If the intron is retained as a result of 
branchpoint deletion, 31 nucleotides would be added between exons 10 and 11. This addition 
would cause a frameshift reading into exon 11, resulting in the addition of 51 new amino acids 
before reading into a stop codon. Exon 11, which is C-terminal to all members of the catalytic 
triad (see Figure 9), contains the substrate binding site as well as the S1 specificity pocket. The 








Figure 15. Schematic of the sbdE(br)623 intronic mutation. 
Exons 10 and 11 are shown as orange boxes with intron, or intervening sequence (IVS), 10 as a 
connecting line. The intronic sequence is expanded below: the deleted 24-bp segment is in blue 
and the lariat branch point consensus sequence is underlined. 
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The final mutation identified, P662L, is found in the sbdVE3 allele. This proline residue is 
very highly conserved across serine proteases and is found in a highly conserved region of the 
protease domain. Two residues N-terminal to this residue is cysteine 660, which forms a salt 
bridge with cysteine 532 within the stem region. This disulfide bridge tethers the protease 
domain to the stem region upon activation cleavage. Altering the proline residue to a lysine could 
result in disruption of this disulfide bridge by misfolding the protein such that the thiol groups of 
the cysteine residues are no longer able to form a covalent linkage. This would result in shedding 
of the protease domain from the protease stem region and the cell surface upon activation 
cleavage. 
iii.) Apparent sbd regulatory mutations 
Of the 12 sbd alleles sequenced, sbd1, sbdE(br)48 and sbdE(br)536 have no changes within the 
coding region that would obviously affect protease function. These alleles are therefore 
presumed to be regulatory in nature, although this would have to be confirmed with further 
experimentation such as steady state RNA or protein level analysis, etc. 
Two polymorphisms were found in sbd1 that are not present in the other sbd alleles 
analyzed. The first change, 1025C>T, is a synonymous change altering a leucine codon from 
CTA to TTA. Neither of these is a preferred leucine codon in Drosophila melanogaster, but the 
alteration from CTA to TTA results in a change to the rarest codon for leucine (Codon Usage 
Database; http://www.kazusa.or.jp/codon/). The second change, 2812G>A, results in alteration 
of the preferred CAG glutamine codon to the less frequently used CAA glutamine codon 
(Akashi, 1995). Thus these changes, while silent with respect to amino acid substitution, could 
potentially affect translation of the Stubble polypeptide through use of non-preferred codons. 
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Adzhubei et al. (1996) suggested that the presence of a rare non-preferred codon in the mRNA 
can be associated with mis-folding of the nascent polypeptide. A recent finding by Kimchi-
Sarfaty et al. (2007) supports this hypothesis. They showed that the human Mutlidrug Resistance 
1 (MDR1) gene containing a single nucleotide silent polymorphism is associated with altered 
conformation and substrate specificity of the MDR1 gene product P-glycoprotein. The 
polymorphism, which was previously linked to altered function of P-glycoprotein, results in 
usage of a rare synonymous codon. 
iv.) Future investigations of Stubble mutations identified in these studies 
To date, the majority of, if not all, published mutational studies of type II transmembrane 
serine proteases have been done in human patients affected by a number of diseases. Such 
studies allow researchers to draw associations between mutations in TTSPs and disease, but they 
do not allow for direct functional analysis of proteases harboring disease-associated mutations in 
an in vivo system. However, taking advantage of the multitude of resources that are available in 
Drosophila, we can express a protease containing a mutation of choice and subsequently analyze 
the direct effect of that mutation on protease function in vivo. 
We plan to use two assays, a leg malformation assay and a bristle defect rescue assay, to 
determine the direct effects of a set of specific mutations on Stubble function during epithelial 
morphogenesis. Using site-directed mutagenesis, I generated 12 individual mutations (Table 15) 
in a full-length wild-type Stubble cDNA and placed them under the control of a heat-shock 
promoter in the vector pCaSpeR-hs (Thummel and Pirrotta, 1991). These mutant constructs will 
be used to make transgenic animals which, upon exposure to high temperatures, will upregulate 
expression of the mutant protein. 
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Previously, Bayer et al. (2003) showed that a 1-hr induction of a wild-type hs-Stubble 
transgene at 0 hr and 3 hr after pupariation (AP) results in a high percentage of severe leg 
malformation in adults and determined that the leg malformation associated with overexpression 
of Stubble is specific to a critical period of leg development between 0 and 10 hours AP. These 
data provide us with an assay which allows for analysis of protease function in animals 
expressing the mutant hs-Stubble transgenes. Staged 0 hr or 3 hr prepupae homozygous for the 
mutant hs-Stubble constructs will be exposed to a constant temperature of 37° for 1 hour. If 
Stubble activity is retained at significant levels upon introduction of the mutant protein, adult 
animals are expected to have an elevated frequency of leg malformation compared to control 
animals in which the transgene is not induced. If, on the other hand, the mutation severely 
reduces Stubble activity, few malformed adults will be observed. One caveat to the interpretation 
of these experiments is that a mutation that causes an increase in Stubble activity will also result 
in a high frequency of malformed adults and would therefore be difficult to distinguish from 
mutations that do not significantly affect Stubble activity. 
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Table 15. Mutant constructs for leg malformation and bristle defect rescue assays 
Mutant Constructs Description 
H573R Alters histidine 573 to arginine (CAC to CGC) 
P137L Alters proline 137 to leucine (CCA to CTA) 
G760S Alters glycine 760 to serine (GGC to AGC) 
G760R Alters glycine 760 to arginine (GGC to CGC) 
S549I Alters serine 549 to isoleucine (AGC to ATC) 
S549N Alters serine 549 to asparagine (AGC to AAC) 
Cys2→Ser Alters cysteine 147 to serine (TGC to TCC) 
Cys3→Ser Alters cysteine 153 to serine (TGC to TCC) 
Cys5→Ser Alters cysteine 173 to serine (TGC to TCC) 
Met1→Leu Alters methionine 1 to leucine (ATG to TTG) 
Met2→Leu Alters methionine 24 to leucine (ATG to TTG) 
S49N Alters serine 49 to asparagine (AGC to AAC) 
 
 
To confirm interpretations based on the leg malformation assay, a second assay, which 
looks for rescue of the sbd bristle phenotype, will be employed. Hammonds and Fristrom (2006) 
showed that the recessive bristle phenotype of the mild hypomorphic mutant, sbd2, could be 
rescued completely with a wild-type hs-Stubble transgene upon a 1-hr induction at 37° at 27.5 hr 
AP. This assay can also be used for analysis of protease function in animals expressing the 
mutant hs-Stubble transgenes. For this assay, mutant transgenes will be placed in a homozygous 
sbd2 background. The resulting hs-Stubble*/hs-Stubble*; sbd2/sbd2 animals will be staged to 27.5 
hr AP, at which point they will be subjected to a 1-hr heat-shock induction at 37°. If the 
introduced mutation causes no significant change from the normal level of Stubble activity, 
100% of adult animals should exhibit normal bristles (i.e. the short bristle phenotype of sbd2 
homozygotes will be rescued). If the mutation reduces Stubble function, incomplete, or no 
rescue, of the bristle defect is expected. As with the leg malformation assay, mutations that 
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increase Stubble activity cannot be easily distinguished from those with close to normal activity 
in this assay. Nevertheless, these assays should provide a useful tool to determine the effect of a 
given mutation on proteolytic activity in vivo. 
Twelve individual site-directed mutant constructs of the Stubble protease will be tested 
for function in the leg malformation and bristle rescue assay systems (Table 15). These 
constructs have been designed to answer a variety of questions. For example, the H573R 
construct mimics the mutation found in the sbd201 allele that has been attributed by Hammonds 
and Fristrom (2006) to the sbd phenotype observed. This construct will allow us to determine 
whether the H573R mutation reduces function of the protease in vivo.  
The P137L mutation, which affects the proline residue directly preceding the disulfide 
knotted domain, was found in the sbd266 allele. This allele also contains a large deletion that 
effectively removes the majority of the protease domain. Thus, it is unclear whether the P137L 
mutation plays any role in altering the function of the Stubble protease in the sbd266 mutant. 
Using a P137L construct will allow us to test whether this mutation, which could potentially 
disrupt folding of the disulfide knotted domain, is capable of reducing Stubble function.  
Mutation of the human matriptase equivalent of Stubble glycine 760 has been implicated 
in autosomal recessive skin disease. Basel-Vanagaite et al. (2007) identified a missense mutation 
which alters this glycine residue to an arginine residue (G827R in matriptase) in patients 
exhibiting ichthyosis with hypotrichosis (ARIH) syndrome. This mutation has been shown to 
result in inactivation of matriptase in an in vitro system (Désilets et al., 2008). The Stubble 
equivalent of G827 in matriptase is also mutated in the Stubble mutant allele sbdE(br)228. In 
contrast to the G827R mutation in matriptase, Stubble Gly760 is substituted for a serine residue. 
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Because the resulting amino acids differ, I have made two mutant Stubble constructs affecting 
Stubble Gly760. The first, G760S, mimics the mutation found in sbdE(br)228. The second, G760R, 
mimics the mutation found in human ST14, the gene encoding matriptase. These constructs will 
allow us to determine whether different types of substitutions at this position affect protease 
function differently and, more importantly, to determine in an in vivo system whether the Stubble 
G760R equivalent of the human matriptase G827R mutation yields an inactive protease. 
The mutation N29I in human trypsinogen, the inactive form of trypsin, has been linked to 
pancreatitis (Gorry et al., 1997). In the Stubble protein, the equivalent residue is Ser549. Because 
mutation at this non-conserved amino acid position has been linked to disease, I decided to alter 
Stubble Ser549 to asparagine and isoleucine. These changes mimic the wild-type residue in 
human trypsinogen (N) and the mutant residue in human trypsinogen linked to pancreatitis (I). 
The S549N and S549I constructs will allow us to determine whether asparagine can functionally 
substitute for serine at position 549 in the Stubble protease, and to determine if isoleucine at this 
position reduces in vivo activity, thus lending support to the data linking the N29I mutation to 
pancreatitis. 
To directly test whether the disulfide knotted domain is necessary for Stubble activity, I 
have made three mutant constructs which alter various cysteine residues within the disulfide 
knotted domain to serine residues. These changes are based on a previous study in the 
Drosophila snake protease in which mutations were introduced into the disulfide knotted domain 
of this protease (Smith et al., 1994). The three cysteine residues altered were chosen based on the 
fact that each is involved in formation of a separate salt bridge necessary for proper folding of 
the disulfide knotted domain. By altering each salt bridge individually, we can assay the 
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requirement for the salt bridge on Stubble protease activity. If the disulfide knotted domain is 
necessary for Stubble function, disrupting any of the salt bridges is predicted to lead to inactivity. 
Two putative start codons are present in the 5’ region of the Stubble protease. Though the 
second has a slightly stronger Kozak consensus, the first is generally given as the start site. 
Because it is unknown which of these methionine residues is used for the start of translation, I 
have made two mutant constructs in which one of the two residues is changed to a leucine 
residue. Alteration of the start codon, whether it be the ATG encoding Met1 or the ATG 
encoding Met2 (amino acid position 24), should eliminate activity of the Stubble protease unless 
the alternate ATG codon can be recruited as the start codon. In the former case, a reduction of 
activity would be expected. If both Met codons can be used to initiate translation, no significant 
effect on Stubble protease activity is expected.  
Finally, the S49N construct targets a putative PKC phosphorylation site in the 
cytoplasmic domain. The PKC phosphorylation site is one of three motifs found within the 
cytoplasmic domain of the Stubble protease. All three motif types, PKC phosphorylation, cAMP 
phosphorylation, and N-myristoylation, have a high probability of occurrence based on the 
consensus patterns used for identification. Although mutations affecting the cytoplasmic domain 
were not observed in the sequenced alleles, the possibility that this domain is a substrate for a 
kinase should be resolved. The introduced mutation alters the serine at position 49 to an 
asparagine, thus eliminating the putative PKC phosphorylation site. Therefore, if this domain is 
necessary for function, it is likely that alteration of this site will inhibit function of the protease. 
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v.) Summary of molecular and genetic analysis of sbd alleles investigated in this study 
I was interested to know if there is a correlation between the type of molecular lesion and 
the genetic characteristics of the sbd alleles tested. The data obtained from sequencing 
experiments, complementation assays and lethal phase analyses are summarized for each sbd 
allele in Table 16. At least one trend is apparent within individual datasets. All mutations 
resulting in truncation of the protease domain or direct disruption of substrate binding exhibit 
predominantly larval lethality with no animals reaching the pupal stage. However, when 
considering mutation type, genetic interaction with Rho1 pathway members and lethal phase 
together, no obvious correlations emerge. 
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Table 16. Summary of genetic data for the mutant sbd alleles  
Strength of interaction with 
Allele Molecular Lesion 
Rho1720 Rho1J3.8 Rho1E3.10 Rho1k02107 zipEbr 
Lethal Phase 
sbd1  Putative Regulatory None None None None Weak Broad Spectrum 
sbd206 Q446X None None Weak Weak Moderate Larval 
sbd258 G755E None None None None Moderate Embryonic 
sbd266 P137L; T587N followed by 292-bpΔ and frameshift + 14aa then stop codon None None None None Weak Larval 
sbdE(br)20 S758F None None None Weak Weak Larval 
sbdE(br)48 Putative Regulatory None None None None Weak Larval w/9% pupariating 
sbdE(br)228 G760S None None None None Weak Pupal w/34% larval 
sbdE(br)448 Q714X None None None None Weak Larval 
sbdE(br)536 Putative Regulatory None Weak Weak Weak Weak Larval 
sbdE(br)623 IVS10:Δlariat consensus None Weak None None Weak Larval w/15% pupariating 
sbdPNRII D737N None None None None Moderate Larval 
sbdVE3 P662L None None None None None Larval w/29% embryonic 
Strength of interaction is defined for the doubly heterozygous class, i.e. Rho1720/+; sbd1/+, as none for a malformation rate of 
less than 5%, weak for a malformation rate of 5%-24%, moderate for a malformation rate of 25%-49% and strong for a 
malformation rate greater than 50%. 
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GPCRs and other candidate regulators of epithelial morphogenesis 
Four genomic regions exhibiting genetic interaction with the Stubble protease in control 
of epithelial morphogenesis have been identified through the primary screen of the non-odorant, 
non-gustatory G protein-coupled receptors in the Drosophila genome. Combined, these regions 
uncover at least 123 genes including 8 GPCRs, as well as a number of other genes that could 
potentially play a cooperative role with Stubble and the Rho1 pathway in regulation of actin 
cytoskeletal dynamics. 
A total of 21 annotated genes are contained within the region uncovered by 
Df(2L)Exel7027 (see Appendix B), including the GPCR gonadotropin-releasing hormone 
receptor (GRHR). The Drosophila GRHR is evolutionarily related to the mammalian GRHR, 
which is involved in various aspects of reproduction (Hauser et al., 1998). Drosophila 
microarray data from whole animals suggests that GRHR is most highly expressed throughout 
larval development and during the first 8 hours of metamorphosis (Arbeitman et al., 2002). This 
expression pattern overlaps that of Stubble and corresponds to the developmental period during 
which the leg discs undergo morphogenesis. 
The genomic region uncovered by Df(2R)Exel6068 contains 16 annotated genes (see 
Appendix B). Two of these, 5-HT1A and 5-HT1B, are G protein-coupled serotonin receptors 
known to be involved in regulation of sleep (Yuan et al., 2006) and circadian rhythms (Yuan et 
al., 2005), respectively. Both receptors are expressed during late embryogenesis in the central 
nervous system (Saudou et al., 1992), but complete expression profiles have not been 
determined. 
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A third deficiency which shows very strong interaction with Sb63b is Df(3L)Exel6084. 
This deficiency deletes genomic region 61B2-61C1, which completely removes 43 annotated 
genes (see Appendix B), including methuselah-like (mthl) 9, mthl10 and mthl14. These are three 
structurally related GPCRs potentially involved in aging and stress response (Brody and 
Cravchik, 2000). Other interesting genes uncovered by Df(3L)Exel6084 are RhoGEF3 and the 
serine-type endopeptidase inhibitors Kaz1-ORFA and Kaz1-ORFB. Also deleted is Enhancer of 
bithorax (E(bx)), an ATP-dependent chromatin remodeling complex that must bind the Ecdysone 
Receptor (EcR) in order for ecdysone-responsive genes to be expressed (Badenhorst et al.,2005). 
A secondary screen using overlapping deletions to further identify the gene(s) within 
Df(3L)Exel6084 which interact with the Stubble protease was also performed (see Table 13 and 
Figure 10). This screen identified two much smaller regions uncovered by Df(3L)BSC128 and 
Df(3L)Exel9057 which split the larger Df(3L)Exel6084 into two separate interacting regions. 
Df(3L)BSC128 has molecular breakpoints 184799-212410 on chromosome 3L. This region 
uncovers the entire coding sequence of 7 genes and partially uncovers 2 additional genes (Table 
17). The GPCR mthl14 is just outside the right breakpoint of the BSC128 deficiency and could 
well be within the deleted region if the right breakpoint of Df(3L)BSC128 is inaccurate. 
Df(3L)Exel9057 has molecular breakpoints 306168-319594 on chromosome 3L, a region which 
contains only 2 genes, four wheel drive (fwd) and CG34264, and fully deletes the coding domain 
of each (Table 17). The GPCRs mthl9 and mthl10 are not deleted by this deficiency. 
None of the genes lying within the breakpoints of Df(3L)BSC128 or Df(3L)Exel9057 
stand out as obvious candidates to interact with Stubble in control of epithelial morphogenesis. It 
is possible that one of these deficiencies removes the regulatory region of a more likely 
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candidate located outside of the deficiency region. Alternatively, the given breakpoints for these 
deficiencies may be inaccurate. In the latter case, the list of genes uncovered by Df(3L)BSC128 
and Df(3L)Exel9057, as presented in Table 17, may not be comprehensive. 
 88
Table 17. Genes uncovered by Df(3L)BSC128 and Df(3L)Exel9057 
Df(3L)BSC128 
Gene Molecular Position Molecular Function 
Mitochondrial carrier homolog 1 (Mtch) 184,635-186,317 transmembrane transporter activity; binding 
rhinoceros (rno) 188,549-198,587 DNA binding; protein binding; zinc ion binding 
mrityu (mri) 200,180-202,165 glycerol kinase activity; protein binding; voltage-gated potassium channel activity 
Glycerol kinase (Gyk) 202,094-205,819 glycerol kinase activity 
Nitrilase and fragile histidine triad fusion protein 
(NitFhit) 203,699-205,311 
bis(5'-adenosyl)-triphosphatase activity; hydrolase activity, acting 
on carbon-nitrogen (but not peptide) bonds; nitrilase activity 
CG13876 206,192-207,112 amine oxidase activity; quinone binding; copper ion binding 
CG7028 207,884-211,462 protein kinase activity; protein serine/threonine kinase activity; ATP binding 
thoc7 211,636..212,687 unknown 
CG16940 212,275..216,483 exoribonuclease II activity; RNA binding 
methuselah-like 14 (mthl14) 247,495-250,314 G protein-coupled receptor activity 
Df(3L)Exel9057 
four wheel drive (fwd) 306,207-319,880 1-phosphatidylinositol 5-kinase activity 
CG34264 317,208-317,621 unknown 
methuselah-like 9 (mthl9) 329,820-332,306 G protein-coupled receptor activity 
methuselah-like 10 (mthl10) 333,475-336,682 G protein-coupled receptor activity 
GPCRs uncovered by Df(3L)Exel6084 are highlighted in blue. None of these GPCRs are uncovered by Df(3L)BSC128 or 
Df(3L)Exel9057, but they are listed to show their proximity to these deficiencies. 
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Finally, the genomic region uncovered by Df(3R)red-P52 contains at least 43 annotated 
genes (see Appendix B). These include two GPCRs, CG9918 and Dopamine Receptor (DopR). 
Interestingly, Srivastava et al. (2005) have recently shown that DopR functions as a cell-surface 
GPCR which may be responsible for some of the rapid actions of ecdysteroids during 
development. It has become apparent that the rapid action of ecdysteroids, such as ecdysone, is 
mediated by mechanisms that alter the levels of secondary messengers which in turn may be 
mediated by the activation of GPCRs. The Drosophila DopR protein is activated by dopamine to 
increase cAMP levels and activate the phosphoinositide 3-kinase pathway. However, the effects 
of dopamine can be inhibited by the binding of ecdysone to the receptor. Once bound, ecdysone 
couples the receptor to rapid activation of the mitogen-activated protein kinase pathway.  
Additional genes uncovered by Df(3R)red-P52 are CG31326, CG9649, Sp212 and 
CG9631, a cluster of four serine-type endopeptidases. It has been suggested that TTSPs may play 
a general role as initiators of protease cascades. This is supported by the fact that certain TTSPs, 
such as matriptase, have been shown to undergo autoactivation in vitro (Oberst et al., 2003; 
Takeuchi et al., 1999). Additionally, all TTSP family members exhibit a strong preference for 
substrates containing an arginine or lysine at their cleavage sites, and have these residues at their 
own cleavage sites suggesting that they may be capable of autoactivation. More support for this 
hypothesis is provided by the discovery that matriptase can activate pro-urokinase plasminogen 
activator (pro-uPA) bound to urokinase plasminogen activator receptor (uPAR) thus activating 
the plasminogen cascade (Kilpatrick et al., 2006). Interestingly, mutant alleles of Stubble interact 
with Notopleural deficiencies which also uncover a cluster of serine proteases (Ruggiero, 2006). 
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Broader impacts 
Misexpression of TTSPs has been implicated in a number of pathologies, thus 
understanding how they function is of great importance. Using Stubble as a model in which to 
study the functional mechanism of TTSPs presents the possibility of defining how extracellular 
hormonal hierarchies, TTSPs and intracellular signaling pathways interact in vivo. Such a model 
of interaction could then be applied toward the understanding of similar interactions in other 
systems. The results of the studies presented here help to bring us a step closer to understanding 
the mechanistic role of the Stubble protease in epithelial development, and thus to understanding 
the mechanism of action of the TTSP family. Through sequence analysis of twelve mutant alleles 
of Stubble, the protease domain was identified as essential for proper protease function. Though 
only the protease domain has been clearly identified as essential, the remaining conserved 
domains cannot be ruled out as necessary components of the functional protein. Further studies, 
such as the leg malformation and bristle defect assays using transgenic animals carrying 
mutations in the remaining domains, are necessary to determine the contribution of these 
domains to Stubble function. In addition to providing a method with which to test functional 
necessity of conserved domains, the leg malformation and bristle rescue assays provide us with a 
system in which to test the in vivo effects of various mutations, including those found in human 
TTSPs implicated in disease, on protease function. Thus, this assay system could prove to be an 
extremely important tool for providing direct evidence that disease-associated mutations are 
capable of reducing or eliminating protease function. 
Another important step in defining the mechanism of action of the TTSP family is the 
identification of TTSP substrates. Using a genetic interaction screen focusing on a subset of 
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GPCRs, I have identified four genomic regions which show significant interactions with Stubble 
mutants. Contained within these regions are a number of genes, including 8 GPCRs, which could 
serve as a link between Stubble and the Rho1 pathway or alternatively as Stubble targets in an 
independent pathway which regulates epithelial development. To establish a clearer picture of 
the types of targets utilized by TTSPs to function in development and homeostasis, further 
studies are necessary to identify their direct substrates in vivo. 
 92
APPENDIX A: GPCR MUTATIONS AND DEFICIENCIES TESTED FOR 
INTERACTION WITH SB63B 
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Stock # Deficiency   GPCRs Affected % malformation with Sb63b  
 
BL7700 Df(1)Exel6223   fz3    8.3 
BL13583  P{y+w+}fz3KG04032   fz3    0.5 
BL9299 Df(1)ED6565    CG4313   not enough data 
BL13875 P{y+w+}KG05130   CG4313   0 
BL17007    P{EP}moodyEP1529   CG4313   3.8 
BL5974 Df(1)X12    CG13758   0 
BL12523 P{w+mGT=GT1}BG00979  CG13758   0 
BL9169 Df(1)ED6712    AlstR    0 
BL8956 Df(1)ED6727    CG6986   0 
BL7708 Df(1)Exel6234   CG16752   0 
BL7710 Df(1)Exel6236   Tre1     4.4 
BL945  Df(1)C149    Tre1    0  
BL10089 P{w+mC=EP}Tre1EP496  Tre1    3.2 
BL9625 Df(1)ED6878    CG12796   0 
BL947  Df(1)HA32    fz4    10.3 
BL13934  P{y+w+}KG02367   fz4    1.6 
BL903  Df(1)V-L3    CG2061   0 
BL11291  P{w+mC}CG2061EP1537  CG2061   2.1 
BL21192  P{w+mCy+}mthl1Ey16157  mthl1    13.8 
BL15318 P{w+mCy+}mthl1EY00861  mthl1    0  
BL8954 Df(1)ED7374    CG4875   2.4 
BL5271 Df(1)D15   CG4875   5.9 
BL18685  PBac{w+mC}CG7536f03720  CG7536   10.5 
BL6217 Df(1)RR79    CG7536   0 
BL22030 P{Mae-UAS.6.11}CG7536GE01344 CG7536   5.6 
BL7762 Df(1)Exel9051   CCKLR-17D1   0.5 
BL7761 Df(1)Exel7463   CCKLR-17D1   0   
BL7764 Df(1)Exel7464   CCKLR-17D1 and 17D3 11.4 
BL13429  P{y+w+}KG01373   CCKLR-17D3   1.1 
BL14884 P{y+w+}KG01171   CCKLR-17D3   4.4 
BL9351 Df(1)ED7635   D2R    4.5 
BL3277 smo3    smo    0  
BL16815 P{w+mCy+}CG9643EY07345  CG9643   1.4 
BL1567 Df(2L)JS17    CG9643   4.4 
BL7500 Df(2L)Exel6014  CG31645   27.5 
BL9185 Df(2L)ED343    CG13995   0 
BL20304 P{w+mCy+}GRHREY11371  GRHR    4.8 
BL11320 PBac{PB}GRHRc03956  GRHR    8.6 
BL7801 Df(2L)Exel7027   GRHR    57.1 
BL7817 Df(2L)Exel8024   CG31720   10.8 
BL7514 Df(2L)Exel6031   Rh5    16.7 
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BL6080 Df(2L)noc11   rk    2.8 
BL3589  rk1    rk    4.4 
BL3590 rk4     rk    not enough data 
BL6965 rk81f2     rk    4.7 
BL10919 P{w+tARry+t7.2AR=wAR}rk11P  rk    0  
BL3212 Df(2L)do1    CG4168   0 
BL7831 Df(2L)Exel7063   kek3    21.6 
BL7527 Df(2L)Exel6045   CG10481   13.8 
BL9683  Df(2R)ED1484   CG14593   2.4 
BL21572   P{y+t7.7w+mC}mxrDG17503  mXr    1.5 
BL7862 Df(2R)Exel7096   mXr    4.1 
BL7863 Df(2R)Exel8047   Cirl    18.8 
BL21398 P{w+mCy+mDint}CirlEY12930  Cirl    0.7  
BL9410 Df(2R)BSC132   CG30340   22.9 
BL6072 stan81f1     stan    0.8  
BL6969  stan192    stan    11.1 
BL6967 stanfz3    stan    0  
BL6969  stan192     stan    8.1 
BL7541 Df(2R)Exel6059   CG13229   3.8 
BL9596 Df(2R)BSC161   mthl4    9.3 
BL16906   P{EPgy2}mthl3EY08706   mthl3    1.2 
BL5574  P{w+mC=lacW}mthl3K10408  mthl3    1.9 
BL10836  P{w+mC}l(2)k01209K08901a  mthl3    2.4 
BL7550 Df(2R)Exel6068   5-HT1A, 5-HT1B  34.5 
BL7998 Df(2R)Exel7166   CG3216   7.4 
BL7912 Df(2R)Exel7184   CG13575   7.7 
BL1473  In(2LR)Px4    mAcR-60C   2.7 
BL7914  Df(2R)Exel7185   CG13579   10.5 
BL18327   PBac{w+mC}CG13579f00432  CG13579   24.1 
BL8046 Df(3L)ED4079   mthl8    0 
BL2577 Df(3L)emc-E12  mthl8,14, 9,10, mth   0 
BL7563 Df(3L)Exel6048   mthl14, mthl9, mthl10 98.0 
BL17137  P{w+mC=EP}EP3542   mthl9    11.0 
BL18405  PBac{w+mC}mthl10f01047  mthl10    17.1 
BL8048 Df(3L)ED4177   mth     0 
BL2400 Df(3L)R-G7   DmsR-2   9.1   
BL8096 Df(3L)ED4287   DmsR-2, DmsR-1  2.7  
BL7571 Df(3L)Exel6092   FR    0 
BL7584 Df(3L)Exel6105   mthl2    26.0 
BL17948  PBac{w+mC=RB}mthl2e01373  mthl2    30.0 
BL6940 Df(3L)XAS96   CG10483   4.2 
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BL19366  PBac{}CG10483PL00048  CG10483   3.5 
BL1420 Df(3L)pbl-X1   mthl6    0 
BL7929 Df(3L)Exel8104   mthl6    5.0 
BL7591 Df(3L)Exel6112   mthl7    4.5  
BL997  Df(3L)AC1    CG6749   7.5 
BL7593 Df(3L)Exel6114   CG33696   3.7 
BL19575  PBac{}CG33696PL00631  CG33696   0 
BL2611 Df(3L)vin5   Rh7    7.4 
BL7595 Df(3L)Exel6116   Rh7    21.4  
BL2612 Df(3L)vin7    GRHRII   0 
BL8070 Df(3L)ED4483   GRHRII   0 
BL5408 l(3)SG111fz1   fz    41.7  
BL3124 Df(3L)fz-Gf3P  fz    6.7 
BL1676  fz1    fz    0 
BL7601 Df(3R)Exel6174   fz    7.7 
BL12512  P{w+mGT=GT1}fzBG00824  fz    0 
BL15624  P{w+mCy+}fzEY03114   fz    3.8 
BL7937 Df(3L)Exel9004   Rh4    0 
BL18260  PBac{w+mC=RB}Rh4e04456  Rh4    16.4 
BL8100 Df(3L)ED4710   CG7497   0 
BL7613 Df(3L)Exel6134   AlCR2    5.9 
BL18622  PBac{w+mC}AlCR2f0316  AlCR2    15.6 
BL6754 Df(3L)fz2    fz2    0 
BL5126 Df(3L)XS533   NPFR76F   8.1 
BL8088 Df(3L)ED4858   NPFR76F   0 
BL8101 Df(3L)ED4978   capaR    0 
BL9700 Df(3L)BSC223   TyrR    5.3 
BL10268  P{hsneo}TyrRneo30    TyrR    3.7 
BL1559 Df(3R)110    5-HT2    3.5 
BL19367  PBac{}5-HT2PL00052   5-HT2    0 
BL7628 Df(3R)Exel6149   CG8007   1.7 
BL9215 Df(3R)ED5495   mthl11    0 
BL8095 Df(3R)ED5558   mthl5    0 
BL18486  PBac{w+mC}CG8784f01901  CG8784   19.4 
BL7974 Df(3R)Exel8158   CG8784, CG8795, mthl12 5.5  
BL18563  PBac{w+mC}CG8795f02573  CG8795   30.9 
BL18464  PBac{w+mC}CG9918f01726  CG9918   17.1 
BL1900 Df(3R)red-P52   CG9918, DopR  87.5 
BL19491  PBac{}DopRPL00420   DopR    15.3 
BL7977 Df(3R)Exel7321   DopR    11.9 
BL2057 Rh61    Rh6    0 
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BL7653 Df(3R)Exel6174   Rh6    1.6 
BL7981 Df(3R)Exel8162   CG31183   5.0 
BL9207 Df(3R)ED5785   Fsh    0 
BL18659  PBac{WH}CG18208f03483  CG18208   24.6 
BL7660 Df(3R)Exel6181   CG18208, Rh2  23.6 
BL19331  P{w+mC=XP}cryd10630  cry    0 
BL3012 Df(3R)D1-BX12   cry, ninaE, Rh3  5.4 
BL1861 ninaE8     ninaE    2.7  
BL2103 ninaE7     ninaE    2.4 
BL5701 ninaE17    ninaE    7.7 
BL9479 Df(3R)ED6027   Rh3    0 
BL9485 Df(3R)ED10838   ETHR, SIFR   3.1 
BL16202  PBac{w+mC=5HPw+}B322  SIFR    2.3 
BL7681 Df(3R)Exel6202   CG11910   6.9 
BL5601 Df(3R)Espl3    boss    4.5 
BL9500 Df(3R)BSC140   boss    6.1 
BL7683 Df(3R)Exel6204   CG12290   4.8 
BL10400  PBac{w+mC=PB}NepYrc01146  NepYr    0 
BL7684 Df(3R)Exel6205   NepYr    20.0 
BL7688 Df(3R)Exel6210   AR-2    lethal - artifact 
BL7692 Df(3R)Exel6214  AdoR    10.4 
BL18848  PBac{w+mC }5-HT7f05214  5-HT7    18.0 
BL5415 Df(3R)t11-e    5-HT7    3.3 
BL18199  PBac{w+mC}CG11318e03837  CG11318   4.1 
BL7919 Df(3R)Exel7379   CG11318, CG15556  2.4 
BL18120  PBac{w+mC}CG15556e03142  CG15556   8.2 
BL7084 Df(4)O2    Glu-RA   8.6 





APPENDIX B: GENES UNCOVERED BY DF(2L)EXEL7027, 




Gene Molecular Function 
CG9232 UDP-glucose:hexose-1-phosphate uridylyltransferase activity; metal 
ion binding 




Nhe3 sodium:hydrogen antiporter activity; solute:hydrogen antiporter 
activity 
CG11327 unknown 
Thrombospondin calcium ion binding 
Gonadotropin-releasing 
hormone receptor 
neuropeptide receptor activity; G-protein coupled receptor activity; 
peptide receptor activity; gonadotropin-releasing hormone receptor 




CG11201 tubulin-tyrosine ligase activity 
CG11323 tubulin-tyrosine ligase activity 





CG11321 protein binding; zinc ion binding 
CG17378 unknown 
nervana 1 sodium:potassium-exchanging ATPase activity; hydrolase activity, 
acting on acid anhydrides, catalyzing transmembrane movement of 









Gene Molecular Function 
serrano unknown 




ubiquitin-protein ligase activity; DNA topoisomerase I binding; zinc 
ion binding 
CG18605 unknown 
CG15105 protein binding; zinc ion binding 
Serotonin receptor 1B 5-HT1 receptor activity; serotonin receptor activity; G-protein 
coupled serotonin receptor activity; amine receptor activity 
CG30126 unknown 
CG15115 unknown 
CG15116 glutathione peroxidase activity 
CG15109 unknown 
Serotonin receptor 1A serotonin receptor activity; 5-HT1 receptor activity; G-protein 
coupled serotonin receptor activity; amine receptor activity 
CG30125 unknown 
CG15117 beta-glucuronidase activity; cation binding 
brother of tout-velu heparan sulfate N-acetylglucosaminyltransferase activity; 
acetylglucosaminyltransferase activity; glucuronyl-galactosyl-




Gene Molecular Function 




MAP kinase tyrosine/serine/threonine phosphatase activity; 




transmembrane transporter activity; binding 
rhinoceros DNA binding; protein binding; zinc ion binding 
mrityu glycerol kinase activity; protein binding; voltage-gated potassium 
channel activity 
Glycerol kinase glycerol kinase activity 
Nitrilase and fragile 
histidine triad fusion 
protein 
bis(5'-adenosyl)-triphosphatase activity; hydrolase activity, acting on 
carbon-nitrogen (but not peptide) bonds; nitrilase activity 
CG13876 amine oxidase activity; quinone binding; copper ion binding 
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CG7028 protein kinase activity; protein serine/threonine kinase activity; ATP 
binding 
thoc7 unknown 
CG16940 exoribonuclease II activity; RNA binding 
Kaz1-ORFA serine-type endopeptidase inhibitor activity 
Kaz1-ORFB serine-type endopeptidase inhibitor activity 





CG34454 serine-type endopeptidase inhibitor activity 
CG34453 unknown 
Enhancer of bithorax ligand-dependent nuclear receptor binding; zinc ion binding 
methuselah-like 14 G-protein coupled receptor activity 
DISCO Interacting 
Protein 2 
protein binding; catalytic activity; transcription factor binding 
CG13879 unknown 





structural constituent of ribosome 
CG34263 unknown 
miple growth factor activity 
miple2 growth factor activity 
CG32845 isomerase activity; protein binding 




RhoGEF3 Rho guanyl-nucleotide exchange factor activity; signal transducer 
activity 
four wheel drive 1-phosphatidylinositol 4-kinase activity 
CG34264 unknown 
CG32344 helicase activity; ATP-dependent RNA helicase activity; ATP 
binding; RNA binding 
CG32343 transcription factor activity 
methuselah-like 9 G-protein coupled receptor activity 




Gene Molecular Function 
Origin recognition 
complex subunit 2 
DNA binding 
roadkill protein binding 
Cyp6d5 electron carrier activity; heme binding; iron ion binding; 
monooxygenase activity 
CG3061 unfolded protein binding; heat shock protein binding 
CG9922 unknown 
transfer RNA:ser2b:88A triplet codon-amino acid adaptor activity 
forkhead box, sub-group 
O 
transcription factor activity; sequence-specific DNA binding 
CG3153 unknown 
CG14358 unknown 
CG9920 unfolded protein binding; ATP binding 
CG9918 G-protein coupled receptor activity; growth hormone-releasing 
hormone receptor activity; neuropeptide receptor activity 
CG12402 protein binding 
Odorant receptor 88a olfactory receptor activity; odorant binding 
CG14357 unknown 
Kif19A microtubule motor activity; ATP binding 
Abelson Interacting 
Protein 
signal transducer activity; protein binding 
twinfilin actin binding; protein-tyrosine kinase activity 
upstream of RpII140 protein transporter activity 
RNA polymerase II 
140kD subunit 








Dopamine receptor dopamine receptor activity; dopamine D1 receptor-like receptor 
activity; G-protein coupled receptor activity 
CG9649 elastase activity; serine-type endopeptidase activity 
CG31326 serine-type endopeptidase activity 
CG33109 unknown 
CG33329 serine-type endopeptidase activity 
CG9631 elastase activity; serine-type endopeptidase activity 
CG9624 unknown 
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trithorax DNA binding; histone lysine N-methyltransferase activity (H3-K4 
specific); sequence-specific DNA binding; protein binding; zinc ion 
binding; transcription factor activity 
CG12207 unknown 
CG3259 unknown 
suppressor of Hairy 
wing 
DNA binding; transcription regulator activity; protein binding; zinc 
ion binding 
RNA polymerase II 
15kD subunit 
DNA-directed RNA polymerase activity; DNA binding; zinc ion 
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